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Abstract
Development of Cell-Active Inhibitors and Activity-Based Probe of Cysteine Cathepsins
by
Dibyendu Dana

Adviser: Professor Sanjai Kumar
Cysteine cathepsins are an important class of enzymes that coordinate a variety of
important cellular processes, and are implicated in various types of human diseases. Still
however, many of their cellular function remain poorly understood. Chemical biology
approaches employing small molecules can be utilized for this purpose. Unfortunately small
molecule probes that are cell-permeable and non-peptidyl in nature are scarcely available.
In this work, first a library of sulfonyloxiranes is synthesized. From this library, 2-(2ethylphenylsulfonyl)oxirane is identified as a selective inhibitor of cysteine cathepsins. Cellbased study reveals that 2-(2-ethylphenylsulfonyl)oxirane is a cell-permeable, covalent, and
irreversible inhibitor of cathepsin B with modest efficacy.
Next, a hybrid-design approach is undertaken to develop a highly potent and selective
peptidyl vinylsulfonates inhibitor (KD-1) of human cathepsin L. Studies involving human breast
carcinoma MDA-MB-231 cells establishes that this inhibitor can successfully block intracellular
cathepsin L activity, and retards the cell-migratory potential of these highly metastatic cells. This
work has been further extended to develop an activity-based probe (KDP-1) of cathepsin L by
suitable modification of KD-1 inhibitory scaffold. KDP-1 has been found to be so far the most
potent activity-based probe of cathepsin L. Cell-based studies are currently underway to
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demonstrate the cellular efficacy of KDP-1. Further, KDP-1 is anticipated to find extensive
applications in proteome-wide analysis of cathepsin L activity in both normal and diseased cells.
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Chapter 1
Introduction to Cysteine Cathepsins

1

1.1 BACKGROUND
Proteases are a class of enzymes that catalyze the hydrolysis of their protein substrates.
They are found in almost all types of living organisms that include mammals, viruses, bacteria,
protozoa, plants and fungi.1 Proteases have been categorized based on their active site catalytic
Proteases

 Aspartate Protease
 Metalloprotease
 Serine Protease
 Cysteine Protease
Figure 1.1. Classification of Proteases.

residues that they use for catalysis. There are four
existing classes of proteases: aspartate protease,
metalloprotease,

serine

protease

and

cysteine

protease (Figure 1.1). The emergence of several
newly discovered proteases necessitate further
classification to differentiate proteases within their
distinct catalytic category into evolutionary families

and clans.2 MEROPS is an evolving database where emergence of newly discovered proteases is
regularly indexed.1,
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Cysteine proteases have been further categorized in three structurally

distinct subclasses: the papain family, the caspase family, and the picornaviridae family.4 The
papain family of enzymes represent majority of the cysteine proteases.5 Cysteine cathepsins
belong to the papain family of enzyme. There are eleven members of cysteine cathepsins
(cathepsin B, C/J/dipeptidyl peptidase I, F, H, L, K, O, S, W, V and Z/X/P) that are primarily
housed in membrane-bound organelles called lysosomes. They have unique catalytic machinery
and tissue specific expression pattern6 and they mediate many essential physiological processes.6
Aberrant expressions of cysteine cathepsins have been associated with different types of
diseases, such as bone loss, autoimmune disease, metabolic syndrome and metastatic cancer.6
Thus, developing inhibitors of cysteine cathepsins have potential to (a) treat a wide range of
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diseases, (b) assessing unknown functions of cysteine cathepsins in various cellular contexts. It is
thus imperative to develop new classes of inhibitors to address the aforementioned issues.

1.2 Regulation and Structure
Cysteine cathepsins are synthesized as preproenzymes which are composed of a signal
peptide, a propeptide and a catalytic domain (Figure 1.2.A).6 Signal peptides are composed of
10-20 amino acid residues, and are responsible for translocation into the endoplasmic reticulum
during mRNA translation.7 Cleavage of signal peptide yields propeptide8 that plays important
role in cathepsin biology.9 The role of propeptide segment is manyfold: (a) it assists in proper
folding of enzyme,7 (b) it uses very specific mannose-6-phosphate receptor (M6PR) pathway to
direct localization to endosomal/lysosomal compartment,7 and (c) it acts as a high-affinity
reversible inhibitor of cognate enzymes that prevents any aberrant zymogen activity.10 Cleavage
of propeptide releases proteolytically active mature cathepsins which vary in length between 214
amino acid residues to 260 amino acid residues.6
Cysteine cathepsins are relatively small monomeric proteins with molecular weights in
the range of 24–35 kDa.11 Cathepsin C is the only exception to this and is a tetramer with a
molecular weight of 200 kDa.11 Determination of papain structure was the first structural
elucidation of papain-like cysteine proteases. Except cathepsin O and W7 three dimensional
structures of all the cysteine cathepsins have been solved (cathepsin B12, cathepsin L13, cathepsin
K14, cathepsin S15, cathepsin V16, cathepsin F17, cathepsin H18, cathepsin X19, and cathepsin C20).
All cysteine cathepsins share the common fold of papain like structure. Cathepsin L has been
chosen as a prototypical of cysteine cathepsin class of enzymes for structural elucidation (Figure
1.2.B).13 Cathepsin L is a bilobal protein that consists of two structurally distinct domains; left
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A

Signal
Peptide

Pro
Domain

Mature
Domain

C

B

Left Domain

Right Domain

Figure 1.2. [A] Representation of cathepsin L as a preproenzyme. [B] Fold of mature
cathepsin L (PDB id: 1icf). The side chains of catalytic residues cysteine 25 (yellow)
and histidine 163 (blue) are shown as ball and stick model. (Carson, 1997). [C] Fold
of procathepsin L (PDB id: 1cjl). The mature enzyme part of cathepsin L is shown in
cyan and the propeptide is shown in maroon. (Turk & Guncar, 2003)
(L) domain and right (R) domain (Figure 1.2.B). The structure of the active cathepsin L
resembles a closed book with the spine at the front13 where two domains form a V-shaped active
site at the interface. Catalytic site of the enzyme lies within the active site that is composed of a
Cys25 (from left domain) and His163 (from right domain). Together they form a thiolateimidazolium ion pair which imparts enhanced nucleophilicity to the cysteine residue.21 The
nucleophilic thiolate residue in turn participates in cleavage of the scissile peptide bond. The left
domain contains three α-helixes. Among these, central α-helix is longest in length and is
composed of 30 amino acid residues.6 On the other hand, right domain represents a β-barrel like
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shape which includes a shorter α-helical motif.13 The propeptide binds to the active site cleft
which makes it inaccessible for substrate binding9, 22 (Figure 1.2).13
The proteolytic activities of mature cathepsins are also regulated by few physiological
factors. For example, cysteine cathepsins are optimally active under acidic environment of
lysosome. Most of them lose activity at neutral pH, except cathepsin S which is active even at
slight alkaline pH.23 It should also be noted that active site cysteine is prone to oxidation. Thus
endosome accumulates cysteine to retain the reducing environment with in the cell.24 Finally,
endogenous inhibitors of cysteine cathepsins maintain the balance of protease activity under
normal physiological condition.25

1.3 Substrate Binding and Specificity
The seminal work by Berger and Schechter in 1967 was the first elucidation of substrate
binding to the active site of cysteine protease.26 Their study examined the influence of substrate
chain length on substrate kinetics. Based on their discovery they have developed a nomenclature
in which individual enzyme pockets have been designated as ‘S’ and substituents approaching
from the peptide substrate have been depicted as ‘P’ (Figure 1.3.A). Three decades later, Turk et
al.27 revisited and redefined the substrate binding to the active site of papain like cysteine
proteases (Figure 1.3.B).13 The active site is comprised of amino acid residues approaching from
both the lobes.11 The L-lobe contributes two shorter loops (Gln19-Cys25, Arg59-Tyr67)
connected by a disulfide bridge (Cys22-Cys63) thus making it an additional loop closure6.
Further, the R-lobe contributes two larger loops6,

13

(Leu134-His159, Asn175-Ser205)

reminiscent of the lid of the β-barrel hydrophobic core.6 The substrate binds along the active site
cleft in an extended conformation6, 27 allowing its side chains to make alternate interactions with
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both lobes. Loops from left lobe accommodate P3, P1 and P2ʹ residues while loops from R-lobe
engage in favorable binding interactions with P2 and P1ʹ.6 Among these subsites, S2 is a deep
pocket whereas S1 and S1ʹ offer just a binding surface.13 Substrate binding beyond S3 and S2’

B

N-terminus

Non-primed sites

P4

P3

S4

S3

Scissile bond

P2

P1

S2

S1

-------

A

Primed
sites
P2’
P1’

S1´

S2´

C-terminus
P3’

S3´

Figure 1.3. [A] Pictorial representation of substrate binding sites according to Schechter

and Berger (1967). Enzyme pockets have been assigned as “S” and substrate peptide
binding to corresponding pockets have been assigned as “P”. [B] Revised substrate
binding to papain like cysteine proteases. Papain numbering has been followed. Reddotted line designates the bond that gets hydrolyzed by cysteine cathepsins.
pocket do not include main chain interaction. Thus these regions are termed as areas but not as
sites.27
The substrate specificity of cysteine cathepsins are governed by physical interactions
between enzyme and the substrates. Depending on the substrate cleavage site, cysteine
cathepsins have been categorized as either an endopeptidase or an exopeptidase, or both (Figure
1.4). Peptidase that cleaves within a substrate polypeptide chain has been coined as
endopeptidase. On the other hand, exopeptidase hydrolyzes the terminal amino acid residue of
6

the substrate peptide. Among cysteine cathepsins five of them are strict endopeptidase (cathepsin
L, S, K, V and F) and three cathepsins serve exclusively as exopeptidase (cathepsin H, X and
C)7. The peptidase activity of cathepsin O and W is yet to be explored. Depending on the cellular
environment, cathepsin B can exert both endo and exopeptidase activity. Exopeptidases have
further been categorized based on the nature of terminal amino acid residue and substrate peptide
length that they cleave. Cathepsin B is a carboxypeptidase whereas cathepsin X acts as a carboxy
monopeptidase.19 Cathepsin C is an aminodipeptidase28 and cathepsin H is an amino peptidase.18

A

B

Figure 1.4. Pictorial representation of [A] endopeptidase, and [B] exopeptidase. Enzyme
pockets have been assigned as “S” and substrate peptide binding to corresponding
pockets have been assigned as “P”. Red-dotted line designates the bond that gets
hydrolyzed by active site cysteine residue of cysteine cathepsins.

1.4 Mechanism of Proteolysis
The cysteine (Cys25) and the histidine (His163) residues of the active site of cathepsin L
form an ion pair which confers enhanced nucleophilicity to cysteine residue. The mechanism of
proteolysis by papain like cysteine cathepsins occurs in a step-wise process (Figure 1.5): (1)
Nucleophilic cysteine (Cys25) attacks the electrophilic carbonyl center of substrate peptide and
forms a tetrahedral anionic intermediate. This intermediate gets stabilized via oxyanion hole
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interactions (2) His163 acts as a general acid and and assists cleavage of the peptide bond via
protonation of leaving amide nitrogen. This leads to expulsion of the C-terminal peptide
fragment, thereby facilitating the formation of thioacyl enzyme intermediate, and (3) Deacylation
of thioacyl enzyme intermediate completes the substrate turnover process, releasing the free
enzyme.

b

a

c

d

Figure 1.5. Proposed mechanism of hydrolysis of substrate peptide by cathepsin L.

1.5 Localization and Physiological Significance
Originally, cysteine cathepsins were considered as redundant class of enzymes, primarily
housed in lysosome, and involved in non-specific terminal protein degradation. Recent studies
have revealed that cysteine cathepsins are not only expressed in lysosome but also in cytoplasm,
8

nucleus and in extracellular spaces as well. While, cathepsin B, L, V, O, H, C, X and F are
ubiquitously expressed in human tissues, cathepsin K, S and W have a more restricted expression
pattern. Variable expression patterns of cysteine cathepsins have implicated them to several
important physiological processes. For example, cysteine cathepsins play important roles in
immunological responses, prohormones activation, bone remodeling, angiogenesis and many
other important physiological processes.6 Cathepsin L, F, S and V participates in MHC IImediated antigen representation that is recognized by CD4+ T cells.6 Cathepsin C activates
various serine proteases and granzyme A and B that helps in limiting acute viral infection.29
Cathepsin W is selectively expressed in natural killer cells and in CD8+ lymphocites and plays
crucial role in cytotoxic killing of abnormal cells.30 Cysteine cathepsins are also involved in
prohormone activation. Cathepsin B has been associated with activation of precursors of βgalactoside31, renin32 and trypsin. Further, cathepsin B, L and K have been associated with
thyroxine production33, while cathepsin H has been implicated in pulmonary surfactantassociated protein processing in human lungs.34
Also, cysteine cathepsins are implicated in skeletal remodeling. Cathepsins K, L, F, S, V
and B have been associated with elastin degradation with varying elastolytic activity.35 Cathepsin
K is predominantly expressed in osteoclast and plays crucial role in bone resorption under
normal and pathological conditions.36
In addition to aforementioned roles, cysteine cathepsins also take part in other
physiological processes. Cathepsin L has been implicated to cell-cycle progression37 and
keratinocyte differentiation and in hair follicle cycle.38 Moreover, cysteine cathepsins degrade
proapoptotic Bcl-2 homolog protein bid and other antiapoptotic Bcl-2 family of proteins which
therefore triggers apoptosis in a synergistic manner.6
9

1.6 Roles in Human Pathology
It is now well established that over-expression and aberrantly regulated activity of
cysteine cathepsins play a major role in promoting many hallmarks of cancer.39 Often, these
require cysteine cathepsins to be overexpressed in the extracellular space. Under normal
physiology, extra cellular space is protected from cysteine cathepsins by neutral pH, endogenous
inhibitors (for example, stefins, cystatins, kininogens, and thyropins)6 and reducing environment.
Nevertheless, pericellular acidification and pathophysiologically reduced anticathepsin
concentrations can help to enhance the activity of cathepsins.7 Elevated level of cathepsins
expression and activity are the key mediators of invasive growth and angiogenesis during
multistage tumorigenesis.40 Aberrantly active of cysteine cathepsins initiate proteolytic cascade
that activate urokinase-type plasminogen activator, matrix metalloproteinases and plasminogen.6
Moreover, these active proteases in conjunction with cysteine cathepsins degrade E-cadherin and
extracellular matrix proteins that is key structural barrier that cells must cross to reach the
vasculature.41 Subsequently, intracellular cysteine cathepsins aid the process by degrading
collagen, as these cells accumulate extracellular matrix via endocytosis.41c, 42
The expression of cysteine cathepsins (e.g. B, F, and L) has indeed been found to be
significantly upregulated in solid tumors from various origins, such as breast, skin, colorectal,
pancreatic, ovarian, brain, head and neck.39b, 43 More importantly, a well-defined role for cysteine
cathepsins in promoting cell invasion and cancer metastasis has recently emerged.44 A high level
expression of cysteine cathepsin B was observed in invasive tumor cells derived from metastatic
cancer patients of distinct origins.45 Deletion of either cysteine cathepsins, B, L or S led to
decreased tumor invasion with tumors progressively returning to a more benign form.43 In a
separate study, cysteine cathepsin X was able to compensate in part for the absence of cathepsin
10

B in a mouse model for mammary cancer.44a In this study, inhibition of cysteine cathepsin X
with a neutralizing antibody resulted in a drastic loss of invasive behavior in cathepsin B null
cultured cells. E-cadherin, an important adherens junction protein that maintains cell-cell
adhesion in epithelial cells, was recently identified as a direct proteolytic target of cysteine
cathepsins B, L and S.43 Since it is well established that functional loss of E-cadherin promotes
cell invasion and metastatic behavior of cancer cells, an effective inhibition of this family of
enzymes is anticipated to provide significant therapeutic benefit in reducing metastatic potential
of solid tumors.46 These studies have led to an interesting hypothesis that promotes a polypharmacological approach to target pro-tumorigenic members of cysteine cathepsins collectively
for the development of effective anti-cancer agents.

1.7 Existing Classes of Reported Cysteine Cathepsin Inhibitors
Pathological significance has prompted cysteine cathepsins as promising drug targets.
Although there are no drugs in use; few are in clinical trial. However, past three decades of effort
has enabled deciphering key protein-ligand interaction that could initiate development of drug
like molecules for cysteine cathepsins. Several different types of inhibitors have been developed
which primarily targets the active site of cysteine cathepsins. Based on their mechanism of
action, these inhibitors have been categorized in different classes. In general, the inhibitory
scaffold is made of three components: (a) recognition region, which engage in physical
interactions with enzyme binding pockets, (b) Address region, which generally confers
additional interactions, and (c) electrophilic warhead, which traps the nucleophilic cysteine
residue of active site. A cartoon diagram illustrating the design of inhibitor is shown below
(Figure 1.6).
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Recognition

warhead

Address

warhead
Active site Cysteine Enzyme

Figure 1.6. Pictorial representation of postulated inhibitor binding to enzyme.

Here is the key representative classes of inhibitors enlisted in following page (Table 1.1).
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Table 1.1. Different classes of existing inhibitors.

Compound classx

Structure

Activity

-1 -1

Peptidyl epoxidea

k2nd = 96250 M s (Cat L)
Not cell active
IC50 = 20 nM (Cat K)
Cell active

Peptidyl aldehydeb

Ki = 22 nM (Cat K)
No cell data available

Acylaminopropanonec

6

Diacylcarbohydrazide

-1 -1

k2nd = 3.1 x 10 M s
(Cat K)
Cell active

d

Miraziridinee

IC50 = 2.05 μM (Cat B)
No cell data available

Peptidyl diazomethylf
ketones

k2nd = 1.5x106 M s (Cat L)
No in vivo data available

-1 -1

6

Peptidyl hydroxamate

-1 -1

k2nd = 3.54 x10 M s (Cat L)
Non selective towards serine
proteases

g

13

7

-1 -1

k2nd = 2.15 x 10 M s (Cat L)
Not cell active

Peptidyl chloromethyl
ketoneh

5

Peptidyl fluoromethyl
ketonei

-1 -1

k2nd = 3.9 x 10 M s (Cat B)
Cell active

Azapenonej

Ki app = 0.041 nM (Cat K)
Cell active

Non-peptidyl nitrilek

IC50 = 0.2 nM (Cat K)
Cell active

IC50 = 2.6 nM (Cat L)
No in vivo data

Peptidyl vinyl sulfonel

5

-1 -1

k2nd = 2.96 x 10 M s (Cat L)
Cell active

Peptidyl acyloxymethyl
Ketonem

14

IC50 = 30.5 nM (Cat L)
Cell active

Thiosemicarbazonen

IC50 = 56 nM (Cat L)
No in vivo data available

Thiocarbazateo

IC50 = 6.9 nM (Cat L)
Cell active

Oxoocarbazatep

IC50 = 164 nM (Cat L)
No Cell data available

Fused ring thiosemicarbazoneq

IC50 = 0.5 nM (Cat K)
No Cell data available

Modified β-lactumr

−1 −1

Organotellurium (IV)s

k2nd = 36,000 M s (Cat B)
Cell active

−1 −1

1, 2, 4-Thiadiazolet

k2nd = 5630 M s (Cat B)
Not Cell active
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IC50 = 0.86 nM (Cat L)
Not Cell active

Cyclopropenoneu

IC50 = 2.5 nM (Cat K)
Cell active

Furanonev

IC50 = 10 nM (Cat K)
Cell active

Bicyclic ketonew

x

Designate literature corresponding to the inhibitor class (a47, b48, c49, d50, e51, f52, g53, h52, i54, j55,

k56, l57, m58, n59, o60, p61, q62, r63, s, t64, u65, v66, w67).

1.8 Perspective of Synthesized Inhibitors and Activity-Based Probe
While numerous studies of cysteine cathepsins have clearly established them as important
therapeutic targets for the development of anti-cancer agents, progress towards development of
small molecule inhibitory agents that are non-peptidyl in nature remains slow. Currently, a
majority of the reported inhibitory agents of cysteine cathepsins are peptidyl- or peptidomimeticbased in nature, making them poorly cell permeable.6 Small molecule inhibitory agents of
cysteine cathepsins that are uncharged and non-peptidyl in nature are therefore desirable so that
they can be further developed as suitable biological inhibitory reagents, in addition to lead
chemotypes for drug development. Furthermore, if the mechanism of inactivation could be
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designed to produce a covalent and irreversible chemistry with the catalytic active site
nucleophilic Cys residue, then the inhibitors could also be developed as activity-based probes
(ABPs) for the functional analysis of cysteine proteases in complex proteomes. Activity-based
probes have indeed found extensive applications in functional annotation of enzymes in their
native biological environments.68
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2.1 Conceptual Design
The advent of E-64 from Aspergillus japonicus, an epoxysuccinyl-derived inhibitory
agent, was a critically important stepping stone for deciphering the undocumented function of
cysteine cathepsins family of enzymes.69 Although, E-64 is a generic non-selective inhibitor of
cysteine cathepsins, structural investigation of the E-64-inhibited complex have subsequently led
to the development of selective cysteine cathepsin B inhibitors (e.g. CA030 and CA074).70 The
marked success of E-64 and its subsequent analogues as effective inhibitors of cysteine
cathepsins relies on the exclusive reactivity of an active site cysteine residue with the
electrophilic “warhead” epoxy group. The catalytic mechanism of cysteine cathepsins involves
participation of this invariant and reactive cysteine residue.71 A close visual inspection of
structure of CA030 and CA074 in complex with cysteine cathepsins revealed that there exists
well-defined binding pockets, S2, and S1’, surrounding the S1 site (Schechter and Berger
nomenclature)72 that prefer to accommodate aromatic hydrophobic groups.70 It was therefore
hypothesized that an arylsulfonyl-substituted oxiranyl moiety could serve as a small molecule

Sufonyloxirane
Figure 2.1. Hybrid design of hypothesized aryl sulfonyloxirane as cysteine cathepsin inhibitor.
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covalent inactivator of cysteine cathepsins, targeting the key residues of the core enzyme active
site (Figure 2.1). This approach envisions that (a) an appropriate binding of inhibitory
compounds within the active site of cysteine cathepsin will allow the reactive Cys residue to be
entrapped by the activated sulfonyloxirane group; and (b) the sulfonyl group will likely mimic
the potential h-bonding interactions that the carbonyl group α to epoxy moiety exhibits in the
CA-030-cysteine cathepsin B inhibited complex70a; and (c) the sulfonyl group will further
enhance the electrophilicity of oxiranyl carbon, compared to a carbonyl group, thereby
facilitating the entrapment of the active site Cys residue. If successfully demonstrated, this class
of molecules could serve as a new type of chemical motif on which selective cysteine cathepsin
inhibitors could be developed in future, exploiting the surrounding S3 and S’ pockets. Such a
strategy has indeed been utilized to develop potent and selective inhibitors of cysteine
cathepsins.73

2.2 Chemistry
Sulfonyloxiranes were synthesized according to scheme 2.1. Reaction of chloromethyl
phenyl sulfone with corresponding aldehyde in presence of potassium hydroxide yield to 1st
generation of sulfonyl oxiranes74 (Scheme 2.1 A). 2nd class of sulfonyloxiranes were synthesized
using a different protocol (Scheme 2.1 B). Reaction of 2-bromoethanol with substituted
thiophenol in presence of base yield to arylthioethanol. Oxidation of arylthioethanol by hydrogen
peroxide

(30%)

provided

2-hydroxy

arylsulfonylethane.

Treatment

of

2-hydroxy

arylsulfonylethane with mesyl chloride in presence of triethylamine at 0 oC leads to
arylsulfonylethene. Further conversion of alkene intermediate to aryl sulfonyloxirane was carried
out using n-BuLi in presence of tert-butyl hydroperoxide.75 3rd generation of compounds were
synthesized according to a literature reported protocol (Scheme 2.1 C).76 Arylthioallyl
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A

B

C

Scheme 2.1. Synthetic schemes utilized for the development of different classes of
sulfonyloxiranes.
intermediate was achieved by reaction between thiophenol and allyl bromide in presence of
potassium carbonate. MCPBA mediated oxidation of the acquired intermediate lead to aryl
sulfonyloxirane with an extra methylene linker. Thiirane was eventually synthesized from the
intermediate sulfonyloxirane using ammonium thiocyanate.

2.3 Results and Discussion
A small library of sulfonyloxirane compounds was therefore synthesized. Cysteine
cathepsin B, a promoter of cancer metastasis, was chosen as the initial inhibitory target to
evaluate the efficacy of a time-dependent loss of enzyme activity (Table 2.1). The initial
screening was performed by incubating a fixed concentration of compounds 1-13 with cathepsin
B under pseudo-first order conditions. A small aliquot of the incubation mixture was withdrawn
at a fixed time interval and the remaining cathepsin B activity was measured in a large volume of
assay mixture (17.5 fold dilution) containing cathepsin B substrate. The IC50 values were
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deliberately not estimated for this library, since they are not considered a good yardstick for
measuring a time-dependent irreversible loss of enzyme activity due to a non-equilibrium
binding mechanism.77
Compounds 1 and 2 which bear a non-polar 4-fluorophenyl and a propyl substituent
respectively at the second carbon of the oxirane ring were non-inhibitory. This result indicated
that a second substitution at the oxirane moiety in this class of molecules was perhaps
detrimental to their inhibitory efficacies. Furthermore, compound 12, which incorporates a
methylene linker between the arylsulfonyl group and oxirane moiety, was also inert. We
surmised that the lack of reactivity of 12 could be due to lack of assistance from a general acid
appropriately positioned in the cathepsin B active site to promote nucleophilic opening of
oxirane ring by Cys29-Sγ residue. So, a thiirane analogue, 13, that potentially contains a better
leaving group thiolate (compared to alkoxide in 12), was synthesized and was also found to be
ineffective. This again indicated that appropriate positioning of arylsulfonyl group with respect
to the reactive oxirane group within the cysteine cathepsin active site was critically important for
its inhibition. Efforts became focused on synthesizing analogues of 2-(arylsulfonyl)oxiranes
where functional variations of the aryl ring was further investigated.
R

(CH 2)n

X

O
S
Ar

O

Figure 2.2. General chemical structure of inhibitory scaffold.
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Table 2.1. Chemical structure of inhibitory library.
Compound ID Chemical Structure (Name)

% Inhibition

1

NI*

F

O2
S
O

2-(4-fluorophenyl)-3-(phenylsulfonyl) oxirane
2

NI*

O2
S
O

2-(phenylsulfonyl)-3-propyloxirane
3

44

O2
S
O

Cl

2-((4-chlorophenyl)sulfonyl)oxirane
4

30

O2
S
O
F3CO

2-(4-(trifluoromethoxy)phenylsulfonyl)oxirane

5

>98

O2
S
O

2-(2-ethylphenylsulfonyl)oxirane

24

6

40

O2
S
O

2-(m-tolylsulfonyl)oxirane

7

42

O
O S O

2-(2,5-dimethylphenylsulfonyl)oxirane
8

35

O2
S
O
OCH3

2-(3-methoxyphenylsulfonyl)oxirane
9

25

O2
S

H3CO

O
OCH3

2-(2,5-dimethoxyphenylsulfonyl)oxirane
10

50

O2
S

Cl

O
Cl

2-(3,5-dichlorophenylsulfonyl)oxirane
11

18

O2
S
O

2-(naphthalen-3-ylsulfonyl)oxirane

25

12

O2
S

NI*

O

2-((phenylsulfonyl)methyl)oxirane
13

O2
S

NI*

S

2-((phenylsulfonyl)methyl)thiirane
* NI : No measurable time-dependent inhibition
Among the synthesized library, compound 5 was found to be most effective in inhibiting
B

A

Figure 2.3. [A] Progress curves indicating a time-dependent loss of cathepsin B activity.
Compound 5 was incubated with cathepsin B under pseudo-first order condition, and the
progress curves were obtained at appropriate times of inactivation (red: 0 min, blue: 11
min, green: 17 min, black: 25 min, and pink: 41 min) using a chromogenic substrate ZRR-para-nitroanilide. [B] Concentration-dependent loss of cathepsin B activity with time.
The points are experimental, and the lines joining them are fitted to obtain the pseudo-first
order inactivation rate constants (kobs).
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cysteine cathepsin B activity. The effectiveness of compound 5 was evident from a progressive
loss of enzyme activity when it was incubated with active cathepsin B (Figure 2.3). No gain in
cathepsin B activity was observed even after dilution of 5-inactivated cathepsin B complex,
thereby indicating that the mechanism of inhibition was perhaps covalent and irreversible in
nature (data not shown). To assess the inhibitory efficacy, inactivation experiments were
performed at appropriate concentrations of compound 5 under pseudo-first order conditions, and
the experimental data thus obtained were analyzed using a simple two-step inhibition model
(Figure 2.4.)
E + I

Ki

ki

E.I

E-I

B

A

-1

(mM )
Figure 2.4.[A] Kitz-Wilson plot of 5-mediated cathepsin B inactivation kinetics. The data
points are fitted to a line that yields (a) Ki = 86 ± 3 μM for the first equilibrium step of
-1

inhibitor binding, and (b) ki = 0.21 ± 0.01 min for the first order inactivation rate
constant. [B] The rate of 5-mediated cathepsin B inhibition is decreased in the presence of
leupeptin (40 nM; blue line), a known competitive inhibitor of cathepsin B, compared to
the control (5% DMSO; red line).
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where Ki represents the reversible equilibrium binding constant for the first step, and ki is the
first order inactivation rate constant for the second irreversible step. To obtain these two
parameters, the following procedure was adopted. The pseudo-first order rate constants of
inactivation (kobs) were obtained at appropriate concentration of 5 ([I]>>[cathepsin B]), and a
Kitz-Wilson analysis was performed to fit the experimentally obtained data (Figure 2.4.A).78
This procedure yielded the thermodynamic binding constant (Ki = 86 ± 3 μM) for the first
equilibrium binding step, and the first order inactivation rate constant (ki = 0.21 ± 0.01 min-1) for
the second irreversible step. We further investigated if the time-dependent inhibition of cathepsin

Figure 2.5. A mass spectrometric analysis of 5-inhibited cathepsin B complex. A mass
difference of 212.1 amu, consistent with the molecular weight of 5 (212.1), is observed in
singly charged 5-inhibited cathepsin B complex (lower panel) compared to uninhibited
cathepsin B enzyme (upper panel). This experiment demonstrates that the mechanism of
5-mediated cathepsin B inhibition is covalent and irreversible in nature.

B by 5 could be alleviated in the presence of a known active site-directed cathepsin B inhibitor,
leupeptin (Ki = 5 nM) .79 This is mainly because if inhibitor 5 were to be an active-site directed
agent, the rate of 5-mediated cathepsin B inactivation reaction would be retarded in presence of a
28

competitive inhibitor competing for the binding to the same active site.80 A protection from
inhibition of cathepsin B inhibition was indeed observed in presence of leupeptin, thereby
indicating that 5 occupied the core cathepsin B active site that harbors the low pKa nucleophilic
Cys29 residue (Figure 2.4.B). A MALDI-based mass spectrometric analysis of the 5-inhibited
cathepsin B complex showed the expected mass increase of 212.1 amu in the cathepsin B
protein. No further mass increase was observed even after prolonged incubation of 5 with
cathepsin B. This result indicates that the mode of inhibition by 5 was indeed covalent and
irreversible in nature and the stoichiometry of inhibition was likely 1:1 (Figure 2.5). This was
important to establish since most cysteine cathepsins do contain multiple cysteines, in addition to
the nucleophilic active site cysteine residue.6

Computational Analysis of 5-inhibited cysteine cathepsin B complex
To understand the potential molecular interactions of 5 with cysteine cathepsin B in the
covalently inhibited complex, computational modeling studies were performed. The CA073inhibited complex of cathepsin B (PDB id: 2DC6) was appropriately modified to incorporate the
inhibitor 5 covalently linked to Cys29-Sγ of cathepsin B active site. A molecular dynamic
simulation (100 ps) was performed on the inhibitory complex and the trajectories of the
molecular dynamics simulation were analyzed. Several interactions between the inhibitor 5 and
cathepsin B active site were noteworthy (Figure 2). While the O3 of sulfonyl oxygen formed a hbond (3.4 Å) with the side chain of Gln23-Nε – a key oxyanion hole residue, its O2 atom was
engaged in a robust hydrogen bond interactions (2.8 Å) with a tightly-bound active site water
molecule (Wtr12). The OH group of inhibitor was also stabilized with two h-bond interactions,
one with the backbone carbonyl of a S2 site residue Gly198 (3.1 Å) and the other with an active
site water (Wtr56) molecule (2.5 Å). The phenyl moiety of the inhibitor was found to be
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Figure 2.6.Stereoscopic view of the energy-minimized structure of the covalently
modified 5-cathepsin B complex. The low pKa active site Cys29 residue is the
site for 5-mediated covalent modification. For clarity, only the inhibitor 5 (yellow)
and the key cathepsin B active site residues are shown. The key h-bonding
distances of 5 with cathepsin B are shown in green. The intramolecular h-bonding
interactions among cathepsin B active site residues near the inhibitor binding site
are depicted in red (heavy atom h-bond donor and acceptor atoms cut off is 3.6 Å).
The position of the primed and non-primed binding pockets on cathepsin B surface
is shown in pink text with underline.
involved in a hydrophobic interaction with a non-polar patch containing Met196, Gly197, and
Gly198 residues of S2 pocket. In addition, the ortho-ethyl group interacted with CH-π
interactions with the aromatic side chains of Trp221 and His110 from S2’ pocket, albeit
weakly.81 A conclusive design of future inhibitory ligand that are selective towards individual
members of the cysteine cathepsin family will require structural elucidation of 5-inhibited
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cysteine cathepsin complex using x-ray crystallography. Our modeling study suggests that orthosubstituted aryl groups containing a negatively charged group could prove to be selective
inhibitory agents towards cathepsin B. Notably, cathepsin B is a unique member of cysteine
cathepsins in that it exhibits endopeptidase, peptidyldipeptidase and carboxypeptidase
activities.82 This broad substrate specificity of cathepsin B has been ascribed to its unique
structural feature that contains a flexible occluding loop (residues 104-126). Since Try221,
His110, and His111 are part of this occluding loop, securing potential interactions from this loop
could result in enhanced selectivity and potency towards cathepsin B. Such features could be
exploited in designing selective inhibitors of cathepsin B.

Compound 5 is inert to external nucleophile and inhibits cysteine cathepsins
selectively.
To evaluate if the presence of an external nucleophile could compromise the inhibitory
efficacy of 5, we carried out cathepsin B inactivation kinetics in the presence of a strong
nucleophile, azide ion (1 mM). No measurable change in inactivation kinetics was evident
thereby indicating that compound 5 is relatively inert to an external nucleophile and unleashes its
covalent reactivity only upon binding to the cathepsin B active site (data not shown). The
selectivity of inhibition of compound 5 towards cysteine cathepsins was investigated next. To do
so, a panel of distinct family of enzymes were chosen and their inhibition by 5 was assessed
(Table 2.2). While inhibition of cathepsin B by 5 was about 1.9-fold more selective compared to
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Table 2.2. Selectivity of inhibition of compound 5 towards cysteine cathepsins as assessed by
the 2nd order enzyme inactivation rate constants.
2nd Order Inactivation Rate
Constant (M-1 Min-1)

Enzyme (Enzyme Family)

a

Cathepsin B (Cysteine Cathepsin)

2441 ± 202a

Cathepsin F (Cysteine Cathepsin)

1300 ± 208b

Cathepsin S (Cysteine Cathepsin)

1196 ± 96b

Cathepsin D (Aspartyl Cathepsin)

65 ± 5b

Cathepsin G (Serine Cathepsin)

NIc

Trypsin (Serine Protease)

NIc

hPTP1B (Protein Tyrosine Phosphatase)

NIc

Calculated from the ki and Ki parameters obtained using Kitz-Wilson Analysis. bDetermined by

measuring pseudo-first order rate constant of inactivation kobs first and dividing the kobs by the
inhibitor concentration. cNI: No apparent time-dependent inhibition even at a concentration as
high as 1 mM during a 1-hour inactivation reaction.
other two prominent members of cysteine cathepsins, namely cathepsin F and cathepsin S, an
aspartyl-utilizing cathepsin D was only weakly (1/38th fold compared to cysteine cathepsin B)
inhibited. Cathepsin G and trypsin protease that use a Ser nucleophile for catalysis remained
inert to inhibition. These experiments suggested that compound 5 is selective towards cysteine
cathepsins that utilize the uniformly conserved and reactive Cys residue for catalysis. The ability
of compound 5 to inhibit protein tyrosine phosphatases (PTPs) was also evaluated. This enzyme
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utilizes a low pKa Cys residue in nucleophilic catalysis. Although 2-(arylsulfonyl)-oxiranes were
previously reported to be modest inhibitors of PTPs75, this enzyme also remained inert to
inhibition by 5. This outcome was observed with the prototypical PTP, hPTP1B, even at a
concentration as high as 1 mM and after a prolonged incubation of one hour. While a conclusive
analysis of this selectivity pattern towards cysteine cathepsins will require structural elucidation
in the 5-inhibited cathepsin B complex, it appears that the presence of an ethyl group at the ortho
position of 2-(phenylsulfonyl)oxirane is significantly favored for binding at the cysteine
cathepsin active site.

2.4 Demonstration of Intracellular Activity of Aryl Sulfonyloxiranes
Before proceeding to evaluate the cellular efficacy of 5 to inhibit cysteine cathepsins in
human cells, it was important to establish its hydrolytic stability at physiological pH. This
consideration was prompted by the oxirane functionality in 5 which could become hydrolytically
unstable as a result of the adjacent electron-withdrawing sulfonyl moiety. This could render the
inhibitor unsuitable for biological applications. Using NMR-based experiments, the half life of 5
at physiological pH (pH = 7.4) was found to be 3.6 hours (Experimental section. Figure 2.10).
This study suggested that compound 5 was relatively stable at physiological pH, and therefore
could be used as an important tool in biological applications.
Cysteine cathepsins play important functional roles in both intracellular and extracellular
signaling events.83 Contrary to popular belief, recent studies strongly suggest that within the cell,
active cysteine cathepsins play regulatory roles in distinct cellular compartments other than
lysosomes, such as nucleus, mitochondrial matrix, cytoplasm, and plasma memebrane.84 For
example, a mis-regulated and an enhanced proteolytic activity of cytoplasmic cysteine cathepsins
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have shown to be linked to tumor invasion.83 Indeed, the invasion potential of both human
melanoma and prostate carcinoma cells was found to be significantly reduced only when these
cells were subjected to cell membrane permeable cysteine cathepsin inhibitors, thereby
suggesting the importance of intracellular cathepsins and their effective inhibition.85 Similarly, a
study by Sloane et al. in human breast carcinoma BT549 cells suggested that only cell-permeable
cysteine cathepsin inhibitors were able to reduce the intracellular proteolysis in these cells.42c
These investigations together underscore the importance of developing non-peptidyl and cell
permeable small molecule inhibitors of cysteine cathepsins; so that their precise function can be
annotated in both normal physiology and human diseases. Unfortunately, cell-permeable and
non-peptidyl inhibitory agents of cysteine cathepsins remain scarcely available today.
Thus in an initial approach, we assessed whether 5 had the potential to inhibit
intracellular cysteine cathepsin B activity in living cells. The metastatic MDA-MB-231 human
breast cell line was chosen for this study since it has been shown that cysteine cathepsin B
activity is upregulated in these cells.86 A highly efficient and specific cathepsin B substrate, ZRR-AMC (kcat/Km=105 M-1s-1), previously employed in cell-based experiments, cell-based
experiments, was chosen for this study.87 While efficient proteolysis of the substrate was evident
in control MDA-MB-231 cells, a significant loss of intracellular cathepsin B activity was
observed in 5-treated cells (Figure 2.7.A). Furthermore, intracellular cathepsin B activity was
shown to decrease in a dose-dependent manner (Figure 2.7.B).
In a second approach, the usefulness of 5 to inhibit cellular cysteine cathepsin activity in
cells was also investigated using a physiologically relevant proteolytic protein target of cysteine
cathepsin B and S, namely E-cadherin, an adherens junction protein.43 The integrity of this
epithelial adhesion protein is critically important in maintaining both intercellular contacts and
34
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Figure 2.7. Effect of inhibitor 5 on cathepsin B activity in breast cancer MDA-MB-231 cells. [A] Cells were
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cellular morphology.88 While it has been shown that a mere loss of cell-cell contacts alone is not
sufficient to promote metastasis, a loss of E-cadherin alone has been shown to be sufficient to
induce this behavior through epithelial-to-mesenchymal transition (EMT), enhanced motility,
resistance to apoptosis, and invasiveness.89 The majority of human tumors are carcinomas that
originate from cells of epithelial tissues where a complete or a partial loss of E-cadherin occurs
as the tumor progressively becomes malignant.90 Thus, the loss of E-cadherin has been directly
linked to invasive migratory behavior of cancer cells.89, 91 In a study involving metastatic MDAMB-231 breast cancer cells which expresses very low levels of E-cadherin,90c the re-expression
of E-cadherin led to the restoration of normal E-cadherins-mediated cell-cell junctions, and a
reversion to a normal epithelial morphology.92 We therefore evaluated the levels of E-cadherin in
MDA-MB-231 cells using an E-cadherin antibody in the presence and absence of inhibitor 5. As
anticipated, a dose-dependent increase in the levels of E-cadherin was observed in a population
of 5-treated MDA-MB-231 cells, as compared to control cells treated only with DMSO (Figure
2.8.A and B). It should also be noted that the overall cellular morphology of metastatic MDAMB-231 cells also changed upon inhibitory treatment (Figure 2.7.A and 2.8.A). This perhaps is
not too surprising since cellular enrichment of E-cadherin is known to have a direct impact on
cellular morphology.88a, b Further experiments will be required to investigate the molecular basis
of altered cellular morphology in MDA-MB-231 cells upon inhibitory treatment. A western blot
analysis of 5-treated MDA-MB-231 cells was also performed that exhibited an enrichment of Ecadherin levels in 5-treated cells, as compared to the control cells (Appendix D). Collectively,
these studies demonstrated that 5 was effective in inhibiting the intracellular activity of cysteine
cathepsins in the invasive MDA-MB-231 breast cancer cells.
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An enrichment of E-cadherin levels as a result of inhibition of cysteine cathepsins by 5 is
anticipated to exhibit a reduced cell migratory behavior.93 To investigate this, the cell motility
assay was carried out
in

presence

and

absence of inhibitor 5
(control,

0.05%

DMSO) on highly
metastatic
cancer
231

breast
MDA-MB-

cells.

As

anticipated, a doseFigure 2.9. The effect of cysteine cathepsin inhibitor 5 on the cellmigratory behavior of metastatic breast cancer MDA-MB-231 cells.
The cell migration phenotype was reduced upon treatment with 5 at
10 μM and 20 μM respectiviely, compared to control. Each reported
change in area value is the average of triplicate measurements with
the corresponding standard deviation value.

dependent
in

decrease

cell

migratory

behavior

of

metastatic

MDA-

MB-231 cells was
observed

(Figure

2.9). This experiment supported the notion that compound 5 inhibits cell migration potential of
these highly metastatic cells. Future experiments will be planned to further optimize the
inhibitory and anti-cell migratory potential of this class of compounds.

2.5 Conclusions.
We have developed a new class of small molecule inhibitors of cysteine cathepsins. A
detailed kinetic and mass spectrometric analysis of cysteine cathepsin B inhibition by 5 was
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performed to determine the kinetic parameters and mode of inhibition. The covalent inhibition of
compound 5 was found to be selective towards cysteine cathepsins. The mechanistically distinct
enzymes, such as aspartyl cathepsin D, serine cathepsin G, serine protease trypsin and a low pKa
cysteine-containing enzyme protein tyrosine phosphatase 1B, were not inhibited by 5. Molecular
modeling studies of 5-inhibited cysteine cathepsin B complex indicated that 5 interacted
favorably with the key active site residues surrounding S1 and S2 pockets. The inhibitor 5 was
shown to be relatively stable to hydrolysis, cell-permeable, and effective in inhibiting
intracellular cysteine cathepsin B activity in metastatic human breast carcinoma MDA-MB-231
cells. We also demonstrated that compound 5 was effective in reducing the migratory potential
of the metastatic MDA-MB-231 breast cancer cell lines. This class of inhibitory agents could
find applications in construction of selective activity-based probe of cysteine cathepsins, and in
the development of selective inhibitory agents for individual members of cysteine cathepsins.94
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2.6 Experimental
2.6.1 Synthesis
General.

13

C NMR and 1H spectra were recorded on a Brucker DPX 400 MHz FT NMR

with automatic sample changer. Chemical shifts (δ) are reported in parts per million (ppm) and
referenced to CDCl3 (7.26 ppm for 1H and 77.0 ppm for 13C), DMSO (2.50 ppm for 1H and 39.5
ppm for 13C), (CD3)2CO (2.05 ppm for 1H and 29.9, 206.7 for 13C) and CD3OD (4.87, 3.31 for 1H
and 49.1 for

13

C). Coupling constants (J) are reported in Hertz (Hz) and multiplicities are

abbreviated as singlet (s), doublet (d), doublet of doublets (dd), triplet (t), triplet of doublets (td),
and multiplet (m). The following materials were purchased from Matrix Scientific (Columbia,
SC,

USA)

m-thiocresol,

dimethylthiophenol,

3-methoxybenzenethiol,

4-(trifluoromethoxy)thiophenol,

3,5-dichlorothiophenol,
2-ethylthiophenol

and

2,52,5-

dimethoxythiophenol. Thiophenol, 2-naphthalenethiol, chloromethyl phenyl sulfone, 4fluorobenzaldehyde, butyraldehyde, disodium salt of silica gel (Merck, grade9385, 230-400
mesh, 60 Ǻ) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Sodium hydroxide,
hydrochloric acid, sodium chloride, sodium sulfate, ammonium chloride, and solvents were
purchased from Fisher Scientific Inc (Pittsburgh, PA, USA).
2-(4-fluorophenyl)-3-(phenylsulfonyl)oxirane (1): The synthesis of this compound was
achieved in a single step by appropriate modification of a published protocol74. The procedure
involved a 1-hour long reaction of 4-fluorobenzaldehyde with (chloromethylsulfonyl)benzene at
room temperature in the presence of a phase transfer catalyst, tetra-n-butylammonium bromide
(10 mol%), in toluene and potassium hydroxide solution. The final purification was performed
using silica gel-based flash chromatography procedure that yielded compound 1 as a white solid.
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Rf = 0.28 Hexane: EtOAc (9:1). Yield: 90%. 1H NMR (400 MHz, (CDCl3) δ ppm: 4.16 (d, J =
1.4 Hz, 1H), 4.58 (d, J = 1.4 Hz, 1H), 7.06 (m, 2H), 7.24 (m, 2H), 7.64 (m, 2H), 7.75 (m, 1H),
7.99 (m, 2H). 13C NMR (500 MHz, CDCl3); δ ppm 56.94, 70.95, 116.11 (d, JC-F = 22.3 Hz, 2C
intensity), 128.00 (d, JC-F = 8.5 Hz, 2C intensity), 128.53 (d, JC-F = 3.3 Hz, 1C), 128.88 (2C
intensity), 129.56 (2C intensity), 134.70, 136.77,163.49 (d, JC-F = 250 Hz, 1C intensity). LRMS
[ESI-MS +ve] calculated for (C14H7FO3S + Na): 301.03, observed: 301.25.
2-(phenylsulfonyl)-3-propyloxirane (2): This compound was synthesized using the same
synthetic protocol as outlined in the synthesis of 1. The final purification was performed using
silica gel-based flash chromatography procedure that yielded compound 2 as a viscous oil. Rf =
0.22 Hexane: EtOAc (9:1). Yield: 85%. 1H NMR (500 MHz, CDCl3) δ ppm: 0.94 (t, J = 7.4 Hz,
3H) 1.47 (m, 2H), 1.57 (m, 1H), 1.66 (m, 1H), 3.63 (m, 1H), 3.90 (d, J = 1.6 Hz, 1H), 7.58 (m,
2H), 7.68 (m, 1H), 7.91 (m, 2H).

13

C NMR (500 MHz, CDCl3) δ ppm: 13.63, 18.93, 32.22,

57.79, 68.30, 128.69 (2C intensity), 129.41 (2C intensity), 134.43, 137.08. LRMS [ESI-MS +ve]
calculated for (C11H14O3S + Na): 249.06, observed: 249.25
2-(4-chlorophenylsulfonyl)oxirane (3): This compound was synthesized by following an earlier
published protocol.75 The final purification was performed using silica gel-based flash
chromatography procedure that yielded compound 3 as a white powder. Rf = 0.50 (hexane/
EtOAc = 9/1). Yield: 63%. 1H NMR (400 MHz, CDCl3) δ ppm: 3.07 (dd, J = 5.4 and 3.7 Hz,
1H), 3.37 (dd, J = 5.4 and 2.1 Hz, 1H), 4.05 (dd, J = 3.7 and 2.1 Hz, 1H), 7.52 (d, J= 8.60 Hz,
2H), 7.81 (d, J= 8.60 Hz, 2H).

13

C NMR (400 MHz, CDCl3) δ ppm: 45.54, 63.25, 129.84 (2C

intensity), 130.31 (2C intensity), 135.25, 141.55. LRMS [ESI-MS +ve] calculated for
(C8H7ClO3S + H): 218.99, observed: 219.00
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2-((4-trifluoromethoxy)phenylsulfonyl)oxirane (4). This compound was synthesized by
following a published protocol.75 The final purification was performed using silica gel-based
flash chromatography procedure that yielded compound 4 as white semi-solid. Rf = 0.29 (hexane/
EtOAc = 19/1). Yield: 40%. 1H NMR (400 MHz, CDCl3) δ ppm: 3.16 (dd, J = 5.3 and 3.6 Hz,
1H), 3.46 (dd, J = 5.3 and 2.0 Hz, 1H), 4.14 (dd, J = 3.6 and 2.0 Hz, 1H), 7.43 (d, J= 8.90 Hz,
2H), 8.01 (d, J = 8.8 Hz, 2H). 13C NMR (400 MHz, CDCl3) δ ppm: 45.58, 63.24, 120.20(q, JC-F =
283 Hz), 121.10 (2C intensity), 131.22 (2C intensity), 134.99, 153.71. LRMS [ESI-MS +ve]
calculated for (C9H7F3O4S + H): 269.01, observed: 269.00.
2-(2-ethylphenylsulfonyl)oxirane (5). This compound was synthesized by following a
published protocol.75 The final purification was performed using silica gel-based flash
chromatography procedure that yielded compound 5 as a pale yellow viscous oil. Rf = 0.28
(hexane/ EtOAc = 19/1). Yield: 72%. 1H NMR (400 MHz, CDCl3) δ ppm: 1.32 (t, J= 7.4 Hz,
3H), 3.09 (q, J = 7.4 Hz, 2H), 3.11 (DD, J = 5.4 and 3.7 Hz, 1H), 3.40 (dd, J = 5.4 and 2.1 Hz,
1H), 4.19 (dd, J = 3.8 and 2.1 Hz, 1H), 7.42 (m, 2H), 7.61 (td, J = 7.7 and 1.2 Hz, 1H), 7.99 (dd,
J = 8.0 and 1.2 Hz, 1H). 13C NMR (400 MHz, CDCl3) δ ppm: 16.15, 26.59, 44.87, 63.65, 126.64,
130.81, 131.33, 134.57, 134.92, 145.86. LRMS [ESI-MS +ve] calculated for (C10H12O3S + H):
213.06, observed: 213.08
2-(m-tolylsulfonyl)oxirane (6). This compound was synthesized by following a published
protocol.75 The final purification was performed using silica gel-based flash chromatography
procedure that yielded compound 6 as a colorless viscous oil. Rf = 0.39 (hexane/ EtOAc = 9/1).
Yield: 70%. 1H NMR (400 MHz, CDCl3) δ ppm: 2.46 (s, 3H), 3.12 (dd, J = 5.4 and 3.7 Hz, 1H),
3.41 (dd, J = 5.4 and 2.0 Hz, 1H), 4.13 (dd, J = 3.7 and 2.0 Hz, 1H), 7.49 (m, 2H), 7.75 (s, 2H).
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13

C NMR (400 MHz, CDCl3) δ ppm: 139.82, 136.66, 135.39, 129.33, 129.06, 125.92, 63.25,

45.35, 21.34. LRMS [ESI-MS +ve] calculated for (C9H10O3S + H): 199.05, observed: 199.25
2-(2,5-dimethylphenylsulfonyl)oxirane (7): This compound was synthesized by following an
earlier published protocol.75 The purification using silica gel column chromatography yielded 7
as colorless viscous oil. Rf = 0.32 (hexane/ EtOAc = 9/1). Yield: 68%. 1H NMR (400 MHz,
CDCl3) δ ppm: 2. 39 (s, 3H), 2.67 (s, 3H), 3.10 (dd J = 5.3 and 3.7 Hz, 1H), 3.88 (dd, J = 5.3 and
2.1 Hz, 1H), 4.18 (dd, J = 3.7 and 2.1 Hz, 1H), 7.25 (d, J = 7.5 Hz, 1H), 7.35 (d, J = 7.5 Hz, 1H),
7.79 (s, 1H).

13

C NMR (400 MHz, CDCl3) δ ppm: 20.33, 20.80, 44.68, 63.36, 131.03, 132.83,

134.87, 135.22, 136.31, 136.78. LRMS [ESI-MS +ve] calculated for (C10H12O3S + H): 213.06,
observed: 213.08
2-(3-methoxyphenylsulfonyl)oxirane (8): This compound was synthesized by following a
published protocol.75 The purification using silica gel column chromatography yielded 8 as a
brownish viscous oil. Rf = 0.27 (hexane/ EtOAc = 9/1). Yield: 70%. 1H NMR (400 MHz, CDCl3)
δ ppm: 3.13 (dd, J = 5.4 and 3.7 Hz, 1H), 3.42 (dd, J = 5.4 and 2.0 Hz, 1H), 3.89 (s, 3H), 4.13
(dd, J = 3.7 and 2.0 Hz, 1H), 7.23 (ddd, J =7.6, 2.5, and 1.9 Hz, 1H), 7.42 (dd, J = 1.9 and 1.6
Hz, 1H), 7.52 (m, 2H).

13

C NMR (400 MHz, CDCl3) δ ppm: 160.15, 137.94, 130.54, 121.27,

120.94, 112.93, 63.25, 55.78, 45.31. LRMS [ESI-MS +ve] calculated for (C9H10O4S + H):
215.04, observed: 214.83
2-(2,5-dimethoxyphenylsulfonyl)oxirane (9): This compound was synthesized by following a
published protocol.75 The purification using silica gel column chromatography yielded 9 as a
white semi-solid. Rf = 0.24 Hexane: EtOAc (9:1). Yield: 78 %. 1H NMR (500 MHz, (CD3)2CO)
δ ppm: 3.19 (dd, J = 5.6 and 3.7 Hz, 1H), 3.31 (dd, J = 5.6 and 2.0 Hz, 1H), 3.83 (s, 3H), 3.97
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(s, 3H), 4.75 (q, J = 3.7 and 2.0 Hz, 1H), 7.28 (m, 3H).13C NMR (500 MHz, (CD3)2CO) δ ppm:
44.56, 55.46, 56.45, 56.47, 62.31, 114.07, 114.71, 121.83, 151.82, 153.37. LRMS [ESI-MS +ve]
calculated for (C10H12O5S + H): 245.05, observed: 245.08
2-(3,5-dichlorophenylsulfonyl)oxirane (10): This compound was synthesized by following a
published protocol.75 The purification using silica gel column chromatography yielded 10 as a
white powder. Rf = 0.67 (hexane/ EtOAc = 9/1). Yield: 45%. 1H NMR (400 MHz, CDCl3) δ
ppm: 3.18 (dd, J = 5.4 and 3.7 Hz, 1H), 3.48 (dd, J = 5.4 and 2.0 Hz, 1H), 4.16 (dd, J = 3.7 and
2.0 Hz, 1H), 7.69 (t, J =1.8 Hz, 1H), 7.82 (d, J=1.8 Hz, 2H).13C NMR (400 MHz, CDCl3) δ ppm:
45.54, 63.19, 127.18 (2C intensity), 134.61, 136.54 (2C intensity), 139.72. LRMS [ESI-MS +ve]
calculated for (C8H6 Cl2O3S + Na): 274.93, observed: 275.00
2-(naphthalen-3-ylsulfonyl)oxirane (11): This compound was synthesized by following a
published protocol.75 The purification using silica gel column chromatography yielded 11 as a
white powder. Rf = 0.27 (hexane/ EtOAc = 19/1). Yield: 78%. 1H NMR (400 MHz, CDCl3) δ
ppm: 3.15 (dd, J = 5.4 and 3.7 Hz, 1H), 3.47 (dd, J = 5.4 and 2.1 Hz, 1H), 4.19 (dd, J = 3.7 and
2.1 Hz, 1H), 7.66 (m, 1H), 7.72 (m, 1H), 7.91 (dd, J = 8.6 and 1.8 Hz, 1H), 7.96 (d, J = 8.6 Hz,
1H), 8.03 (dd, J = 8.4 and 1.0 Hz, 1H), 8.06 (d, J = 8.4 Hz, 1H), 8.53 (d, J = 1.0 Hz, 1H).13C
NMR (400 MHz, CDCl3) δ ppm: 45.43, 63.39, 123.09, 127.85, 128.06, 129.60, 129.71, 129.76,
131.02, 132.20, 133.69, 135.75. LRMS [ESI-MS +ve] calculated for (C12H10O3S + H): 235.05,
observed: 235.08
2-((phenylsulfonyl)methyl)oxirane (12): This compound was synthesized by following the
literature-reported protocol95 and its characterization was found to be consistent with the
previously reported NMR spectra.96
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2-((phenylsulfonyl)methyl)thiirane (13): This compound was synthesized by following the
literature-reported protocol95 and its characterization was found to be consistent with the
previously reported NMR spectra.97

2.6.2 Enzymology, physiochemical, and mass spectrometric studies
General.

Following enzymes and their substrates were purchased from Enzo Life Sciences

(Farmingdale, NY, USA): cathepsin B (BML-SE198), cathepsin D (BML-SE199), cathepsin S
(BML-SE453), cathepsin F (BML-SE568), cathepsin G (BML-SE283), human PTP1B (BMLSE332), Z-Arg-Arg-pNA (BML-P138), Z- Arg-Arg-AMC (BML-P137), Z-Phe-Arg-AMC
(BML-P139), Suc-Ala-Ala-Pro-Phe-pNA (BML-P141), Mca-Gly-Lys-Pro-Ile-Leu-Phe-Phe-ArgLeu-Lys(Dnp)-D-Arg-NH2 (BML-P145), Z-Val-Val-Arg-AMC (BML-P199). N-alpha-benzoylDL-arginine-p-nitroanilide

(BAPNA)

(B4875),

trypsin

(T1426),

leupeptin,

para-

nitrophenylphosphate and bovine serum albumin (A2153) were purchased from Sigma-Aldrich
(St. Louis, MO, USA). All the biological grade buffers were used and were purchased from
Sigma-Aldrich (St. Louis, MO, USA). All enzyme kinetics experiments (unless otherwise stated)
were carried out at 30 °C in appropriate buffer condition with 5% DMSO concentration. The
mass spectra were acquired using a MALDI-microMX mass spectrometer (Waters Corp,
Milford, MA) instrument equipped with an N2 laser operating at 10 Hz, using delayed extraction
and positive ion linear mode analysis. For measuring the initial rates of enzyme catalyzed
reaction, a temperature-controlled steady-state arc lamp fluorometer equipped with Felix 32
software (Photon Technology Instrument,

Birmingham,

NJ, USA) and a UV-Vis

spectrophotometer (Model λ25; Perkin Elmer Inc., Waltham, MA, USA) was used.
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Methodologies for assessing time-dependent inactivation of cysteine cathepsin B and
inhibitor screening procedure:
The inactivation reaction of human liver cathepsin B (net 175 nM) with inhibitor was
performed under pseudo first order condition ([I]>>[E]) in a 0.5 ml eppendorf tube maintained
at 30 °C in a temperature controlled bath. Freshly made Inhibitor stock solution (in DMSO) was
used for each experiment. A previously reported cathepsin B assay procedure was employed. 98
Cathepsin B enzyme was first activated for 10 minutes in sodium phosphate buffer (100 mM, pH
6.0) containing 5 mM DTT and 1 mM Na2EDTA. The inactivation reaction was initiated by the
addition of inhibitor where DMSO concentration was maintained at 5%. After suitable time
intervals, an aliquot of 10 μl of incubation mixture was withdrawn and added to an assay mixture
(net assay volume 175 μl) that contained 3mM of Z-RR-pNA (Km = 0.9 mM) substrate at 30 °C.
A progress curve was recorded at 405 nM, and the enzyme activity was determined by measuring
the initial rates of substrate turnover. For initial screening experiments, the assay protocol
remained the same except that the concentration of all inhibitors was fixed at 500 μM and the
residual enzyme activity was measured after 10 minutes of reaction.
Method for estimation of kinetic parameters for 5-mediated cathepsin B inhibition:
To obtain Ki and ki parameters for the two step inhibition model, the following procedure
was adopted. A sequence of independent cathepsin B inactivation experiments were performed at
25, 50, 75, 100, and 150 μM of 5 under pseudo-first order condition ([I]>>[Cathepsin B]) and
enzyme activities were monitored at appropriate time intervals. The data thus obtained at each
concentration were plotted and fitted to the following equation At = Af – (Af-A0)e(-kobs* t) where
At = enzyme activity at time t of cathepsin B inactivation, Af = final cathepsin B activity at
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infinite time of inactivation, A0 = initial enzyme activity at zero time of inactivation, and kobs =
pseudo-first order rate constant of inactivation. Kitz-Wilson analysis is then performed to
estimate the reversible equilibrium binding constant Ki for the first step, and the first order
inactivation rate constant (ki) for the second irreversible step, as described elsewhere.78 For,
demonstration that compound 5 is active site-directed, the inactivation reaction of 5 with
cathepsin B was performed in presence of an established competitive inhibitior of cathepsin B,
leupeptin (40 nM) and the residual cathepsin B activity was measured, as described above. Such
a methodology has been previously utilized to demonstrate the active site-directed nature of
inhibition for previously uncharacterized covalent and irreversible inhibitory agents.80, 99
Cathepsin F inhibition assay:
A previously reported enzyme assay procedure was adopted with appropriate
modifications.100 The enzyme was activated for 10 minutes in 50 mM potassium phosphate
buffer at pH 6.5 containing 2.5 mM DTT, 2.5 mM Na2EDTA, and 1.0 mg/ml BSA at 25 °C. The
inactivation reaction was initiated by addition of inhibitor 5 to activated human cathepsin F (net
1.1 nM). After suitable time intervals, an aliquot of 10 μl of incubation mixture was withdrawn
and the enzyme activity was measured in an assay buffer (net 175 μl) containing 3 μM of Z-FRAMC fluorogenic substrate (Km = 0.44 μM) at 25°C.
Cathepsin S inhibition assay:
For assaying cathepsin S activity, a previously published protocol was followed with
appropriate modification.101 Thus, cathepsin S enzyme was activated first in the 100 mM
potassium phosphate buffer (pH 6.5) containing 5 mM DTT, 5 mM Na2EDTA for 10 minutes.
The inactivation reaction of human Cathepsin S (net 134.6 nM) with inhibitor 5 (75 μM) was
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initiated. After suitable time intervals, an aliquot of 3 μl of incubation mixture was withdrawn
and the enzyme activity was measured in assay buffer (175 μl; 8% DMSO) containing 250 μM
of Z-VVR-AMC (Km >100 μM102; Ex/Em: 365/440 nm) fluorogenic substrate.
Cathepsin G inhibition assay:
A previously reported assay conditions were followed.103 The enzyme was activated in 20
mM Tris-HCl buffer (pH 7.4) containing 500 mM NaCl for 15 minutes. The inactivation reaction
of human Cathepsin G (net 7.66 nM) with inhibitor 5 was initiated. After suitable time intervals,
an aliquot of 10 μl of incubation mixture was withdrawn and the enzyme activity was measured
in assay buffer containing 3.4 mM Suc-AAPF-pNA cathepsin G substrate (Km= 1.7 mM).
Cathepsin D inhibition assay:
The enzyme was activated in 50 mM sodium acetate buffer (pH = 4) containing 5 mM
DTT and 1 mg/ml bovine serum albumin. The inactivation reaction of human Cathepsin D (net
20 nM) with inhibitor was initiated. After suitable time intervals, an aliquot of 1 μl of incubation
mixture was withdrawn and added to an assay mixture (net assay volume of 175 μl) that
contained

40

μM

of

Mca-Gly-Lys-Pro-Ile-Leu-Phe-Phe-Arg-Leu-Lys(Dnp)-D-Arg-NH2

[Mca=(7-methoxycoumarin-4-yl)acetyl] cathepsin D substrate (Km = 3.7μM). Enzyme activity
was monitored by measuring fluorescent enhancement over the time.
Serine protease (trypsin) inhibition assay:
The assay procedure was adopted from an earlier published protocol 104. Trypsin enzyme
solution was freshly made using 1 mM HCl just before the inactivation reaction. Inactivation
reaction was initiated by the addition of inhibitor to a pre-activated trypsin (net concentration of
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190-200 U/μl). After suitable time intervals, an aliquot of 2 μl incubation mixture were
withdrawn and added to a 67 mM sodium phosphate assay buffer (net assay volume of 175 μl)
which contained 3 mM N-alpha-benzoyl-DL-arginine-p-nitroanilide (BAPNA, Km = 0.94 mM)
as a substrate. Enzyme activity was monitored by measuring the initial rate of substrate
consumption at 410 nm.
Protein tyrosine phosphatase 1B (PTP1B) inhibition assay:
The time-dependent inactivation kinetics of 5 with PTP1B was performed as described
before.
Mass-spectral studies:
Cathepsin B was activated and incubated with inhibitor under conditions similar to those
used for kinetics studies for 10 minutes. Both 5-inhibited cathepsin B inhibitory complex and
control (5% DMSO) were prepared for matrix-assisted laser desorption/ionization mass
spectrometry using the ultra-thin layer essentially as published.105 Samples were saturated in a
1:9 ratio with a saturated solution of recrystallized α-cyano-4-hydroxycinnamic acid in 50%
formic acid/ 33% isopropyl alcohol/ 17% water (v/v/v; Fisher Scientific- all HPLC grade).
Acceleration potential of 12,000 V and an extraction pulse of 1,950 V with a delay time for 410
ns were used. Spectra were smoothed and baseline corrected using MassLynx (Waters Corp) and
calibrated pseudo-internally using equine apomyoglobin.
Hydrolytic stability of inhibitor 5:
To study the hydrolytic stability of compound 5, NMR experiment was carried out in
following manner. First, sodium phosphate buffer (10 mM) of pH 7.4 was prepared. A portion (5
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ml) of this buffer was lyophilized and re-dissolved in deuterium oxide. This step was repeated
thrice so as to ensure a complete H/D exchange. The buffer components were re-dissolved in
deuterium oxide (5 ml). The hydrolysis experiment was carried out under pseudo first order
reaction condition. A stock solution of 5, freshly made in deuterated DMSO was added to
deuterated phosphate buffer (total volume 500 μl; net concentration of 5 at 2.5 mM) and NMR
spectra were recorded after appropriate time intervals. The rate of hydrolysis was measured by
comparing the integration values of initial and final compounds. The rate constant of hydrolysis
was obtained by fitting the data to a single exponential decay curve (It=I0e-k*t) and the half was
calculated using the following equation: t1/2=0.693/k.

Figure 2.10. Estimation of the half life of compound 5 at physiological pH 7.4.
The relative peak intensity of 5 was plotted against time and the data was fitted
To a single exponential. The t1/2 was estimated to be 3.6 hours.
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Molecular Modeling
The molecular modeling studies were performed on a Dell PowerEdge 6000 server
operating on Red Hat Enterprise Linux ES release 4. The CH3CONHCysCONHCH3 peptide
covalently attached to inhibitor 5 at the terminal aliphatic carbon was built with open oxirane
ring in Builder module of Maestro 7.5 software and partial charges on each atoms were
determined in Jaguar (Schrodinger Inc., New York, NY, USA) using density-functional theory
(DFT) calculation with B3LYP/6-31G* basis set. The coordinate file of cathepsin B (PDB id:
2DC6) was downloaded and appropriately modified at pH 7.0 to include inhibitor 5 covalently
linked to Cys29Sγ residue using Insight II software (Accelrys Inc., SanDiego CA, USA). The
partial charges on the atoms of inhibitor were assigned from DFT calculations and the complex
was soaked with a 15 Å spherical shell of water with Cys29Sγ as the center. The resulting
complex was energy minimized (10,000 steps of Steepest Descent). A molecular dynamics run
(100 ps) was then carried out on the energy-minimized complex using Consistent Valence
Forcefield (CVFF) force field in Discover standalone program (Accelrys Inc., San Diego CA,
USA). The trajectories from molecular dynamic run were saved every 2 ps and analyzed. During
the energy minimation procedure and the molecular dynamics simulations, no constratins were
imposed on 5-cathepsin B inhibitor complex.
Cell culture:
All the cell culture reagents were purchased from Invitrogen (Carlsbad, CA). MDA-MB231 cells (American Type Culture Collection, Manassas, VA) were cultured on 10-cm plates
(BD FalconTM) at 37°C and 5% CO2 in Iscove’s Modified Dulbecco’s medium with L-glutamine
(IMDM), 10% fetal bovine serum, and antibiotics (1% penicillin/streptomycin and 0.5 μg/ml
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fungizone) as described earlier.106 Cells were passaged at 1:3 ratios every 3–4 days and
subcultured by 0.25% trypsin-EDTA treatment. Cells were re-plated one day prior to experiment
so that the cell density was 70-80% on the day of the experiment.
Confocal microscopy:
For live-cell imaging, cells were seeded to Poly-D-lysine coated 35mm-glass bottom
dishes (MatTek; Ashland, MA) and grown overnight in complete medium. Prior to imaging, cells
were treated in 15 mM HEPES containing phenol-red (PR)-free complete medium. To reduce
photo-bleaching, 0.6u of Oxyrase enzyme per ml (Oxyrase Inc.) was added to the PR-free
medium containing 10 mM sodium-lactate, as previously described.107 Cells were incubated with
either dimethylsufoxide (DMSO, 0.1% v/v) as vehicle control, or varying concentrations of 5 for
20 minutes at 37oC, followed by an additional 10 minutes of incubation with the substrate Z-RRAMC (25 μM net) of 5. Images of cells were acquired using an inverted Leica TCS-SP5 confocal
microscope (Leica; IL) by Plan apochromat 63x1.4 oil objective lens (numerical aperture 0.61.4). An argon ion laser (25%) was used to generate an excitation at 488 nm, and pinholes were
typically set to 1–1.5 Airy units. Results for every condition are the average over three
independent experiments in each of which 8-10 cells were analyzed by Image J.
Immunofluorescence:
Cells, grown on 35-mm glass coverslips in 6-well plate for 24 hrs, were treated with the
vehicle (0.1% DMSO), or appropriate concentrations of cathepsin B inhibitor for 20 minutes at
37oC. After treatment they were fixed in 3.7% PFA at room temperature for 10 minutes followed
by 30 sec incubation in microtubule-stabilizing and cell-permeabilizing buffer (80 mM PIPES, 1
mM MgCl2, 4 mM EGTA, 0.5% Triton-X100) at room temperature. The samples were then
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washed thrice with phosphate-buffered saline (PBS) and incubated in immunoblocker (2% BSA,
0.1% sodium azide) for 15 minutes at 37oC.
For immunostaining, cells were incubated overnight at 4oC with monoclonal mouse
antibody E-cadherin (1:100) (Santa Cruz Biotechnology, Santa Cruz, CA) followed by
incubation with secondary Alexa 594-conjugated donkey anti-mouse antibody (1:300)
(Invitrogen, Carlsbad, CA) for 2 hrs at 37oC.88b,

108

DNA was stained with Hoechst 33342 (1

mg/ml in PBS). Cells were mounted on clean glass slides using mounting media DABCO
(Invitrogen). Samples were examined with a Plan-Neofluar 40x oil immersion objective lens
(numerical aperture 0.75) using a Zeiss Axio Imager-M2 upright fluorescence microscope (Zeiss,
Heidelberg, Germany). Results for every condition are the average of three independent
experiments in each of which 28 cells were analyzed by ImageJ software.
Western-blot analysis:
Cell lysate proteins were (50 µg) resolved by an 8% SDS-PAGE on Duracryl followed by
electrophoretic transfer to 15x15 cm Immobilon-P (Millipore, Bedford, MA) nitrocellulose
membranes. After blocking with 5% nonfat dry milk, membranes were incubated overnight at
4oC with E-cadherin (1:500) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and DM1A-αtubulin mouse monoclonal antibody (1:5000) (Sigma-Aldrich, St. Louis, MO, USA), followed by
incubation with peroxidase-conjugated secondary antibodies and chemiluminescence detection
(Supersignal West Pico, Pierce).
Cell Motility Assay:
The effect of inhibitor 5 on cell migratory behavior of MDA-MB-231 cells was evaluated
by following a slight modification of an earlier published protocol.109 Thus MDA-MB-231 cells
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were plated as concentric circles on a 10-well glass slide pre-coated with 1% BSA through a 10hole cell sedimentation manifold (CSM, Inc., Phoenix, AZ) followed by incubation at 37 oC and
5% CO2. After removal of the manifold, cells were treated with control vehicle (0.05% DMSO)
or appropriate concentrations of inhibitor 5, and incubated for 6 hours at 37 oC. Images were
acquired by a digital camera (Moticam 2000) attached to an inverted Nikon Diaphot microscope
both before (t0) and after inhibitory treatment (t6). Motility of cells was calculated by the change
in total area (in square micrometers) by Image J software. Each reported value is the average of
triplicate measurements with corresponding standard deviation value (S.D.).
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Chapter 2
Part B.
Serendipitous Discovery: Base-Catalyzed
Synthesis of Allyl and Vinyl Phenyl Sulfones
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2.7. Background
A diverse group of important synthetic intermediates can be widely accessed through the
chemistry of the aryl sulfonyl functional group110. Vinyl and allyl sulfones are important
members of this class of compounds and are used as intermediates in a variety of organic
transformations.111 For example, vinyl aryl sulfones have been successfully utilized to develop
potent and selective inhibitory agents and activity-based probes of cysteine proteases.112
Similarly, allyl aryl sulfones are convenient intermediates for synthesizing natural products, such
as [(−)-erythrodiene], squalene, and coenzyme Q10.113
Most synthetic methods for preparation of vinyl sulfones start with an alkene or 1-haloalkene
derivative and involve multiple steps.112a,

114

One of the challenges in the synthesis of vinyl

sulfones lies in the increased preference for ,  over ,  unsaturation. This often leads to
isomeric mixtures of vinylic and allylic sulfones.114a,

115

Isomerically pure vinyl sulfones are

easily synthesized in systems where ,  unsaturation is not possible.116 Most allylic sulfones are
either prepared by treating vinylic sulfones with a base, or by a direct conversion of allylic
alcohols or alkenes in the presence of a metal catalyst.114a, 117 Recently, the reaction of benzylic
alcohols with sulfinyl chlorides and arenesulfonyl cyanides with allylic alcohols were utilized to
produce allylic sulfones.118

2.8 Discovery
In our effort to make vinyl sulfones as inhibitors of certain classes of therapeutically
important enzymes, we followed established literature protocols for analogous reactions that
involved the use of NaH with sulfonyl methylphosphonate116,

119

. Thus, 1 was treated with 2-

phenylacetaldehyde in the presence of 2.0 equiv NaH at 0 °C resulting in a quantitative
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conversion to allylic sulfone 9 without any trace of the desired vinylic sulfone 2 (Scheme 2.2).
Even when we reduced the number of equivalents of NaH to 1.1 equiv, only allylic sulfone 9
formed, again with no vinylic sulfone 2. The use of one equiv of NaH however yielded
predominantly the vinylic sulfone 2 (4:1 vinylic:allylic mixture). Surprisingly, a further

Scheme 2.2. Yield (calculated based on precursor aldehyde): 2 (81%), 3 (74%), 4 (71%), 5
(66%), 6 (69%), 7 (75%), 8 (73%), 9 (94%), 10 (83%), 11 (81%), 12 (81%), 13 (84%), 14
(82%), 15 (85%).
reduction of NaH (0.9 equiv) led to exclusive formation of vinylic sulfone 2, with no trace of the
allylic sulfone 9. Importantly, all reactions went to completion within an hour, and any additional
time of reaction did not affect either the regioselectivity of the products or their yield. This is an
interesting finding since many of the literature methods involve significantly higher reaction
times, and often give products with compromised regioselectivity114.
Our efforts to ascertain the structure of 2 was hampered by previously misreported
spectral characteristics of this compound114b,

120

. Therefore, a complete structural analysis by

NMR was undertaken to unambiguously establish the structures of 2 and 9 (Table 2.2 for
complete 1H and

13

C assignment for 2 and 9). The 1H-1H scalar coupling between the olefinic

protons was more than 15 Hz indicating a trans geometry for both compounds. The relative
position of the double bond with respect to the phenyl ring was established from 1H-13C long
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range correlation (HMBC) experiments (Appendix B). In addition, we also detected NOE
between methylene protons and the ortho protons of the adjacent phenyl ring in 2 while a similar
NOE was observed between one olefinic proton and the ortho protons of the adjacent phenyl ring
in 9. A complete assignment of 1H and

13

C NMR peaks for 2 and 9 also established the

characteristic spectral differences between the α, β unsaturation versus the β, γ unsaturation. For
example, the methylene carbon in 9 experiences the –I effect of the sulfone and is 23 ppm
downfield shifted compared to the methylene carbon in 2. The -R effect of the sulfone can be
observed on the β olefinic carbon in 2 which is substantially downfield shifted and observed at
145.42 ppm. The structure of 2 was also confirmed by X-ray crystallography (Figure 2.11).121

Figure 2.11. X-ray crystal structure of 2. ORTEP drawing with complete
numbering of atoms, viewed approximately normal to the alkene plane.
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Table 2.2. 1H and 13C NMR Chemical Shifts for vinyl phenyl sulfone, 2 and allyl phenyl sulfone,
9.a

13

1

C shifts (ppm)

H shifts (ppm), J values in Hz

Compound 2

Compound 9

Compound 2

Compound 9

1

131.53

60.51

6.26 (dt, 15.1, 1.7)

3.96 (dd, J=7.6, 1.2)

2

145.42

115.12

7.16 (dt, 15.1, 6.5)

6.10 (dt, 15.8, 7.6)

3

37.64

139.25

3.56 (dd, 6.5, 1.7)

6.36 (dt, 15.9, 1.2)

a

140.5

138.30

-

-

b

127.64

128.55

7.86 (dd, 8.4, 1.4)b

7.88 (dd, 8.2, 1.3)b

c

129.27

129.14

7.54 (tt, 7.5, 1.2)b

7.54 (tt, 7.5, 1.3)b

d

133.34

133.84

7.62 (tt, 7.5, 1.3)b

7.64 (tt, 7.5, 1.3)b

a’

136.21

135.73

-

-

b’

128.84

126.64

7.13 (dd, 8.2, 1.4)b

7.28 (m)

c’

128.89

128.70

7.32 (tt, 7.5, 1.4)b

7.30 (m)
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d’
a

127.11

7.26 (tt, 7.5, 1.4)b

128.57

7.28 (m)

Chemical shifts were measured relative to TMS at 20 oC on a 500 MHz NMR spectrometer.

Solvent is CDCl3. To make comparison of shifts easier, the numbering of carbons is kept the
same in both compounds and is shown in the structures above. Complete assignments were made
using 1D 1H and

13

C as well as 2D homo- and hetero-nuclear correlation and NOESY

experiments.
b

These protons exhibit second-order splitting, the appearance of which may deviate by a small

extent from the pattern mentioned here depending on the spectrometer frequency.
After clearly establishing the structures of 2 and 9, we used six additional arylacetaldehyde
substrates to probe the generality of the regio- and stereochemistry (Scheme 2.2). Thus, when a
panel of 2-arylacetaldehydes, shown in scheme 1, were synthesized122 and subsequently treated
with 1 using 0.9 and 1.1 equiv of NaH, the corresponding vinyl and allyl sulfones in high yields
were obtained with exclusive E stereochemistry. To probe the importance of aryl substitution at
the 2-position of acetaldehyde, the aliphatic aldehyde butanal was first examined. Thus, when
butanal was allowed to react with 1 in the presence of 0.9 equiv of NaH, only the vinylic
derivative 16 was observed with diminished stereoselectivity (Table 2.3). At 1.1 equivalents of
NaH, a reaction of butanal with 1 gave allyl sulfone, but a substantial amount of vinyl sulfone
was also present (Table 2.3). When 2.2 equiv. of NaH was used, the reaction gave allylic sulfone
19 as the major product, again with diminished stereoselectivity. Table 2.3 lists the distribution
of regioisomers with their E/Z ratios obtained for a panel of 2-alkylacetaldehydes. With 0.9
equiv of NaH, exclusive formation of the vinylic sulfones was observed but again the
corresponding allylic sulfones formed with diminished regio- and stereoselectivity when 1.1
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equiv of NaH was used. These results, taken together, indicate that the base-controlled regio- and
stereochemistry is sensitive to the nature of the α-substituent of the acetaldehyde.
Table 2.3. Treatment of 1 with 2-alkylacetaldehydes under varying NaH concentrations.

Percent distribution of Vinyl and Allyl Isomers and their E/Z ratiosa
R=

With 0.9 equiv NaH

With 1.1 equiv NaH

-CH2CH3

100% 16 (5/1), 0% 19

58% 16 (13/1), 42% 19 (2/1)

-CH(CH3)2

100% 17 (1/0), 0% 20

67% 17 (1/0), 33% 20 (1/1)

-(CH2)4CH3

100% 18 (7:3), 0% 21

72% 18 (7/3), 28% 21 (1/1)

a

Peaks corresponding to each isomer were integrated and normalized from the NMR spectrum of

the crude mixture. 1H NMR, 13C NMR, and mass spectrometric characterization of 16 and 19 are
included in the experimental section. Complete characterization of NMR peaks was not carried
out for compounds 17, 18, 20, and 21 as these compounds were previously reported and
characterized123.
To probe if a strong base such as NaH was essential for the observed regio- and
stereoselectivity, we carried out the reactions of 1 with 2-phenylacetaldehyde and 1 with butanal
in the presence of a weaker base, potassium tert-butoxide (1.1 equiv). In both cases, the
exclusive regioselectivity was lost as the reaction with 2-phenylacetaldehyde yielded a 11:14
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mixture of 9 and 2 while butanal gave a 17:3 mixture of 16 and 19. To assess if a base stronger
than NaH could drive an exclusive conversion of butanal to allylic sulfones 19, a reaction of 1
with butanal was carried out in the presence of 1.1 equiv of n-butyllithium. Surprisingly, the
reaction yielded exclusively the vinyl sulfones 16, without any trace of corresponding allylic
sulfones. This perhaps could be due to the compromised stability of n-butyllithium reagent in the
reaction mixture under our experimental conditions (typically 0-10 °C, 1.5 hrs). Thus, it appears
that an optimal basicity of NaH is required for this regio- and stereoselective transformation.
Considering the results from Table 2.3, it is clear that aryl substitution at the γ position of
the vinylic sulfones plays a crucial role for regio- and stereoselectivity, and only a catalytic
amount of NaH is necessary for the formation of allyl sulfone from vinyl sulfone. To gain
further insight into the mechanism of this transformation, a computational analysis was
undertaken [All calculations were carried out in vacuum using Spartan program. (Spartan '10,
version 1.1.0, Wavefunction Inc., Irvine, CA, 2011). The structures of the E and Z isomers of 2,
9, 16, and 19 were minimized using MM2 calculations. The minimized structures were then
further subjected to DFT calculations using B3LYP/6-311G* basis set to obtain the equilibrium
geometries and total energies. From the energy-minimized structures of 2 and 16, one of the
methylene protons was removed to create the anion.]. The standard heat of formation (ΔH0f) by
T1 method124 as well as total energy (ΔE) by DFT methods showed that allylic sulfones 9 and
19E were thermodynamically more stable than their corresponding vinylic sulfones 2 and 16E
by a comparable amount [ΔΔH0f favors 9 and 19E by -13.1 kJ/mol and -14.9 kJ/mol
respectively, and ΔE favors 9 and 19E by -20.4 kJ/mol and -24.1 kJ/mol respectively]. The
energy-minimized geometry for the sulfones as well as the ΔE value for the conversion of 2 to 9
agrees closely with the estimated values reported by Lee et al.125. To understand why only
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vinylic sulfone 2 would convert easily to allylic sulfone 9 with catalytic NaH but not the
vinylic75sulfone 16, we compared the differences between the neutral sulfones and the anions
obtained after proton abstraction to approximate the energy barrier for this conversion. DFT
calculations at the B3LYP/6-311G* level showed that the difference is lower by 41.3 kJ/mol for
2 compared to 16E. It can be inferred that the resonance stabilization of the resulting negative
charge by the aromatic ring (23 – Scheme 2.3) plays a dominant role in the ease with which the
allylic sulfone forms. Based on our experimental observation and computational analysis, a
plausible mechanism for the quantitative conversion of 1 to 2 and 9 is proposed. The reaction
proceeds through a cyclic Wittig intermediate 22 which readily breaks down to yield the vinylic
sulfone 2126. When a catalytic excess of base is present, an acidic proton is abstracted from 2 to
form a resonance-stabilized carbanion 23. This carbanion acts as a base to abstract another
proton from 1 to form the thermodynamically stable product 9, thus regenerating carbanion 23

Scheme 2.3. Proposed mechanism of the formation of allylic sulfone 9 when catalytic
excess of sodium hydride is used.
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which can subsequently turn over another substrate molecule 2. Catalytic participation of NaH
has been observed previously.127
Having established the effect of conjugation from one phenyl moiety and to gain further
support for our postulated mechanism, we hypothesized that 2,2-diphenylacetaldehyde will form
the allyl sulfone even more favorably. We therefore synthesized 2,2-diphenylacetaldehyde128 and
carried out a reaction with 1 using 0.9 equiv NaH. Not surprisingly, the reaction exclusively gave
the allylic sulfones 24 (Scheme 2.4), a compound that has been previously prepared by other
methods.129 When this reaction was repeated with 0.5 equiv of NaH, it still resulted in a
quantitative conversion of the 2,2-diphenyl-acetaldehyde to 24 (50% overall yield) with no trace
of the vinyl sulfone. Indeed the ΔE calculations by DFT methods show that formation of 24 is
favored by 35.9 kJ/mol over its corresponding vinylic isomer (i.e. about twice the amount
calculated for 9). Both experimental results and theoretical calculations confirm that an extended
conjugation favors the formation of the allylic sulfones over the corresponding vinylic
analogues.

Scheme 2.4. Exclusive formation of allyl sulfone under varying base
equivalent.

2.9 Concluding Remarks
In conclusion, we have described a convenient general route to synthesize vinylic and
allylic sulfones that contain an aromatic group on the γ-carbon of the sulfones. The reactions
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described here proceed in just 1 hr time, do not require any metal catalyst, and yield exclusively
a single product with high regio- and stereoselectivity. Importantly, this can be achieved simply
by changing the amount of NaH used in the reaction mixture. Thus, while a catalytic excess of
NaH (1.1 equiv) produces the allylic sulfones in quantitative yield upon reaction of 1 with 2arylacetaldehydes, a sub-stoichiometric amount of NaH (0.9 equiv) produces only the
corresponding vinylic sulfones.130
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2.10 Experimental
General

13

C NMR and 1H spectra were recorded on a Brucker DPX 400 MHz FT NMR

with automatic sample changer. Chemical shifts (δ) are reported in parts per million (ppm) and
referenced to CDCl3 (7.26 ppm for 1H and 77.0 ppm for 13C), (CD3)2CO (2.05 ppm for 1H and
29.9, 206.7 for

13

C). Coupling constants (J) are reported in Hertz (Hz) and multiplicities are

abbreviated as singlet (s), doublet (d), doublet of doublets (dd), triplet (t), triplet of doublets (td),
and multiplet (m).
Synthesis
Typical

procedure

for

synthesis

of

2-8:

A

solution

of

diethyl

((phenylsulfonyl)methyl)phosphonate (500 mg, 1.7 mmol, 1 equiv) in dry tetrahydrofuran (2
mL) was added dropwise to a stirring suspension of sodium hydride (39 mg, 1.53 mmol, 0.9
equiv) in dry tetrahydrofuran (5 mL) at 0 °C under inert condition. After 30 minutes a solution of
α-substituted acetaldehyde (1.7 mmol, 1.0 equiv) in dry tetrahydrofuran (3 mL) was added to the
reaction mixture. Stirring was continued for an hour. The reaction was quenched by addition of 5
mL of sodium bisulfate (5 wt% solution). The solution was concentrated under vacuum, diluted
with water (10 mL) and extracted with ethylacetate (3 x 5 mL). The combined organic extracts
were washed with saturated aqueous sodium bicarbonate and brine, dried over sodium sulfate,
filtered and concentrated under vacuum. Purification by flash column chromatography (silica
gel; 97:3 hexane:ethylacetate) provided the desired product.
Compounds 9-15 were synthesized by following the same protocol used in the synthesis of 2-8
except that 1.1 equiv (44.9 mg, 1.87 mmol) of NaH was used. For the synthsis of 24, E and Z
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isomers of 16-21, appropriate amount of NaH was utilized (see Table 2). The characterizations of
compounds are as follows:
(E)-((3-phenylprop-1-en-1-yl)sulfonyl)benzene (2). Yield: 81%. [see Table 1 for 1H and

13

C

NMR aasignments]. LRMS [ESI-MS +ve] calculated for (C15H14O2S+Na): 281.1, observed:
281.3.
(E)-4-(3-(phenylsulfonyl)allyl)-1,1'-biphenyl (3). Yield: 74%. 1H NMR (400 MHz, (CDCl3) δ
ppm: 3.60 (d, J = 6.6 Hz, 2H), 6.30 (d, J = 15.2 Hz, 1H), 7.14-7.66 (m, 13H), 7.88(m, 2H). 13C
NMR (100 MHz, (CDCl3) δ ppm: 37.27, 127.04, 127.39, 127.61, 127.67, 128.82, 129.28,
129.29, 131.64, 133.37, 135.21, 140.12, 140.47, 140.58, 145.30. LRMS [ESI-MS +ve] calculated
for (C19H16O2S+Na): 357.1, observed: 357.2
(E)-1-(3-(phenylsulfonyl)allyl)naphthalene (4). Yield: 71%.

1

H NMR (500 MHz, (CD3)2CO) δ

ppm: 4.14 (d, J = 6.4 Hz, 2H), 6.51(d, J =15.1 Hz, 1H), 7.20-8.09 (m, 13H).

13

C NMR (125

MHz, (CDCl3) δ ppm: 34.36, 123.77, 125.71, 125.85, 126.27, 127.10, 127.35, 127.76, 128.76,
129.35, 131.68, 131.97, 133.28, 133.53, 134.07, 141.22, 145.47.

LRMS [ESI-MS +ve]

calculated for (C19H16O2S+Na): 331.1, observed: 331.2
(E)-1-methyl-2-(3-(phenylsulfonyl)allyl)benzene (5). Yield: 66%. 1H NMR (500 MHz, CDCl3) δ
ppm: 2.20 (s, 3H), 3.56 (dd, J = 6.2 and 1.4 Hz, 2H), 6.13 (dt, J = 15.2 and 1.4 Hz, 1H), 7.05 (d, J
= 6.9 Hz, 1H), 7.16 (m, 4H), 7.53 (t, J =7.6 Hz, 2H), 7.61 (t, J = 7.6 Hz, 1H), 7.85 (d, J = 7.6 Hz,
2H). 13C NMR (100 MHz, (CDCl3) δ ppm: 19.3, 35.4, 126.5, 127.4, 127.6, 129.2, 129.6, 130.6,
131.5, 133.3, 134.6, 136.3, 140.6, 145.1. LRMS [ESI-MS +ve] calculated for (C16H16O2S+Na):
295.1 Observed: 295.0Calculated Mass for (C16H16O2S+Na): 295.1 Observed: 295.0
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(E)-1-chloro-2-(3-(phenylsulfonyl)allyl)benzene (6). Yield: 69%. 1H NMR (500 MHz, CDCl3) δ
ppm: 3.63 (dd, J = 6.3 and 1.4 Hz, 2H), 6.23 (tt, J = 15.0 and 1.4 Hz, 1H), 7.13 (dt, J = 15.0 and
6.3 Hz, 1H), 7.17 (m, 1H), 7.22 (m, 2H) 7.37 (m, 1H), 7.53 (t, J =7.7 Hz, 2H), 7.62 (t, J = 7.7 Hz,
1H), 7.86 (d, J = 7.7 Hz, 2H).

13

C NMR (100 MHz, (CDCl3) δ ppm: 35.4, 127.3, 127.6, 128.8,

129.3, 129.9, 130.8, 131.9, 133.3, 134.1, 134.3, 140.4, 143.7. LRMS [ESI-MS +ve] calculated
for (C15H13ClO2S): 315.0 Observed: 315.0
(E)-1-methyl-4-(3-(phenylsulfonyl)allyl)benzene (7). Yield: 75%. 1H NMR (400 MHz, CDCl3)
δ ppm: 2.32 (s, 3H), 3.51 (dd, J = 6.6 and 1.8 Hz, 2H), 6.25 (dt, J = 15.0 and 1.8 Hz, 1H), 7.00
(d, J = 8.0 Hz, 2H) 7.11 (d, J = 8.0 Hz, 2H), 7.13 (dt, J = 15.0 and 6.6 Hz, 1H), 7.52 (tt, J = 7.6
and 1.4 Hz, 2H), 7.61, (tt, 7.6 and 1.4 Hz, 1H), 7.86 (dd, J = 7.6 and 1.4 Hz, 2H). 13C NMR (100
MHz, (CDCl3) δ ppm: 21.0, 37.2, 127.6, 128.7, 129.3, 129.6, 131.3, 133.1,133.3, 136.7, 140.6,
145.8. LRMS [ESI-MS +ve] calculated for (C16H16O2S + Na): 295.1 Observed: 295.0
(E)-1-methoxy-4-(3-(phenylsulfonyl)allyl)benzene (8). Yield: 73%.

1

H NMR (400 MHz,

CDCl3) δ ppm: 3.50 (dd, J = 6.6 and 1.3 Hz, 2H), 3.79 (s, 3H), 6.23 (dt, J = 14.9 and 1.3 Hz, 1H),
6.84 (d, J = 8.6 Hz, 2H) 7.03 (d, J = 8.6 Hz, 2H), 7.13 (dt, J = 14.9 and 6.6 Hz, 1H), 7.53 (tt, J =
7.6 and 1.3 Hz, 2H), 7.61, (tt, 7.6 and 1.3 Hz, 1H), 7.86 (dd, J = 7.6 and 1.3 Hz, 2H).

13

C NMR

(100 MHz, (CDCl3) δ ppm: 36.8, 55.3, 114.3, 127.6, 128.1, 129.3, 129.9, 131.2, 133.3, 140.6,
145.9, 158.7. LRMS [ESI-MS +ve] calculated for (C16H16O3S+Na): 311.1 Observed: 311.0
(cinnamylsulfonyl)benzene (9). Yield: 94%. [see Table 1 for 1H and

13

C NMR assignments].

LRMS [ESI-MS +ve] calculated for (C15H14O2S+Na): 281.1, observed: 281.2
(E)-4-(3-(phenylsulfonyl)prop-1-en-1-yl)-1,1'-biphenyl (10). Yield: 83%.

1

H NMR (500 MHz,

(CD3)2CO) δ ppm: 4.12 (d, J = 7.6 Hz, 2H), 6.22 (m, 1H), 6.53 (d, J =15.9 Hz, 1H), 7.32-7.51
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(m, 5H), 7.59-7.77 (m, 7H), 7.92 (d, J = 7.4 Hz, 2H).

13

C NMR (125 MHz, (CD3)2CO) δ ppm:

59.66, 116.24, 126.69, 127.09, 127.10, 127.51, 128.37, 128.90, 129.14, 133.67, 135.32, 137.96,
139.30, 140.24, 140.77. LRMS [ESI-MS +ve] calculated for (C19H16O2S+Na): 357.1, observed:
357.2
(E)-1-(3-(phenylsulfonyl)prop-1-en-1-yl)naphthalene (11). Yield: 81%. 1H NMR (400 MHz,
(CDCl3) δ ppm: 4.09 (dd, J = 7.65, 1.0 Hz, 2H), 6.13 (m, 1H), 7.08 (d, J = 15.6 Hz, 1H), 7.387.96 (m, 12H).

13

C NMR (100 MHz, (CDCl3) δ ppm: 60.69, 118.51, 123.50, 124.30, 125.57,

125.99, 126.26, 128.56, 128.68, 128.86, 129.21, 130.84, 133.46, 133.53, 133.80, 136.98, 138.28.
LRMS [ESI-MS +ve] calculated for (C19H16O2S+Na): 331.1, observed: 331.2
(E)-1-methyl-2-(3-(phenylsulfonyl)prop-1-en-1-yl)benzene (12). Yield: 69%. 1H NMR (500
MHz, (CDCl3) δ ppm: 2.13 (s, 3H), 3.98 (d, J = 7.6 Hz, 2H), 5.98(dt, J =15.5, 7.6 Hz, 1H), 6.56
(d, J = 15.5 Hz, 1H), 7.10 (dd, J = 7.4, 2.0 Hz, 1H), 7.16 (td, J = 7.4, 2.0 Hz, 1H), 7.19 (td, J =
7.4, 2.0 Hz, 1H), 7.34 (dd, J = 7.4, 2.0 Hz, 1H), 7.54 (tt, J = 7.5, 1.3 Hz, 2H), 7.64 (tt, J = 7.5, 1.3
Hz, 1H), 7.90 (dd, J = 7.5, 1.3 Hz, 2H). 13C NMR (100 MHz, (CDCl3) δ ppm: 19.5, 60.7, 116.6,
125.9, 126.2, 128.4, 128.6, 129.1, 130.3, 133.8, 134.9, 135.6, 137.3, 138.4. LRMS [ESI-MS +ve]
calculated for (C16H16O2S+Na): 295.1, observed: 295.0
(E)-1-chloro-2-(3-(phenylsulfonyl)prop-1-en-1-yl)benzene (13). Yield: 84%. 1H NMR (400
MHz, (CDCl3) δ ppm: 4.00 (d, J = 7.6 Hz, 2H), 6.12 (tt, J =15.7, 7.6 Hz, 1H), 6.71 (d, J = 15.7
Hz, 1H), 7.21 (m, 2H), 7.31 (m, 1H), 7.46 (m, 1H), 7.55 (tt, J = 7.4, 1.4 Hz, 2H), 7.65 (tt, J = 7.4,
1.4 Hz, 1H), 7.89 (dd, J = 7.4, 1.4 Hz, 2H).

13

C NMR (100 MHz, CDCl3) δ ppm: 60.5, 118.2,

127.0, 127.1, 128.5, 129.2, 129.5, 129.7, 133.2, 133.8, 133.9, 135.4, 138.2. LRMS [ESI-MS +ve]
calculated for (C15H13ClO2S): 315.0 Observed: 315.0
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(E)-1-methyl-4-(3-(phenylsulfonyl)prop-1-en-1-yl)benzene (14). Yield: 82%. 1H NMR (400
MHz, CDCl3) δ ppm: 2.34 (s, 3H), 3.94 (d, J = 7.6 Hz, 2H), 6.05 (dt, J = 15.6 and 7.6 Hz, 1H),
6.32 (d, J = 15.6 Hz and 1H) 7.11 (d, J = 8.0 Hz, 2H), 7.18 (d, J = 8.0 Hz, 2H), 7.53 (tt, J = 7.6
and 1.4 Hz, 2H), 7.63 (tt, 7.6 and 1.4 Hz, 1H), 7.88 (dd, J = 7.6 and 1.4 Hz, 2H). 13C NMR (100
MHz, (CDCl3) δ ppm: 21.3, 60.6, 114.0, 126.6, 128.6, 129.1, 129.4, 133.0, 133.7, 138.4, 138.6,
139.2. Calculated Mass for (C16H16O2S+Na): 295.1 Observed: 295.0
(E)-1-methoxy-4-(3-(phenylsulfonyl)prop-1-en-1-yl)benzene (15). Yield: 85%. 1H NMR (500
MHz, CDCl3) δ ppm: 3.81 (s, 3H), 3.93 (d, J = 7.7 Hz, 2H), 5.96 (tt, J =15.6, 7.7 Hz, 1H), 6.31
(d, J = 15.6 Hz, 1H), 6.84 (dd, J = 8.7 Hz, 2H), 7.23 (d, J = 8.7 Hz, 2H), 7.54 (t, J = 7.7 Hz, 2H),
7.64 (t, J = 7.7 Hz, 1H), 7.88 (d, J = 7.7 Hz, 2H).

13

C NMR (100 MHz, CDCl3) δ ppm: 55.3,

60.6, 112.6, 114.1, 127.9, 128.5, 128.6, 129.1, 133.7, 138.5, 138.7, 159.9. LRMS [ESI-MS +ve]
calculated for (C16H16O3S+Na): 311.1 Observed: 311.0
(E)-(pent-1-en-1-ylsulfonyl)benzene(16E). 1H NMR (500 MHz, CDCl3) δ ppm: 0.92 (m, 3H),
1.50 (m, 2H), 2.23 (m, 2H), 6.33 (d, J = 15.0 Hz, 1H), 7.00 (m, 1H) 7.54 (m, 3H), 7.87 (m, 2H).
13

C NMR (125 MHz, CDCl3) δ ppm: 13.6, 20.9, 33.4, 127.5, 129.3, 130.4, 133.3, 140.7, 147.1.

LRMS [ESI-MS +ve] calculated for (C11H14O2S+Na): 233.1, observed: 233.3.
(Z)-(pent-1-en-1-ylsulfonyl)benzene (16Z). 1H NMR (500 MHz, CDCl3) δ ppm: 0.92 (m, 3H),
1.50 (m, 2H), 2.64 (m, 2H), 6.33 (m, 2H), 7.54 (m, 3H), 7.92 (m, 2H).

13

C NMR (125 MHz,

CDCl3) δ ppm: 13.7, 21.9, 29.6, 127.2, 129.3, 130.5, 133.4, 141.8, 147.5. LRMS [ESI-MS +ve]
calculated for (C11H14O2S+Na): 233.1, observed: 233.2.
(E)-(pent-2-en-1-ylsulfonyl)benzene(19E). 1H NMR (500 MHz, CD3OD) δ ppm: 0.88 (t, J =
7.52Hz, 3H), 1.98 (m, 2H), 3.87 (d, J = 7.31 Hz, 2H), 5.37(m, 1H), 5.56 (m, 1H), 7.71 (m, 2H),
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7.71 (m, 1H), 7.86(m, 2H).

13

C NMR (125 MHz, MeOD-D4) δ ppm: 12.0, 25.2, 59.1, 115.2,

128.3, 128.8, 133.5, 138.3, 142.8. LRMS [ESI-MS +ve] calculated for (C11H14O2S+Na): 233.1,
observed: 233.2.
(Z)-(pent-2-en-1-ylsulfonyl)benzene(19Z). 1H NMR (500 MHz, CD3OD) δ ppm: 0.71 (t, J =
7.55 Hz, 3H), 1.77 (m, 2H), 3.98 (d, J = 8.01, 2H), 5.37 (m, 1H), 5.70 (m, 1H), 7.62 (m, 2H),
7.71 (m, 1H), 7.89 (m, 2H).

13

C NMR (125 MHz, MeOD-D4) δ ppm: 12.3, 20.1, 54.2, 114.5,

128.2, 128.9, 133.6, 138.6, 140.7. LRMS [ESI-MS +ve] calculated for (C11H14O2S+Na): 233.1,
observed: 233.2.
(3-(phenylsulfonyl)prop-1-ene-1,1-diyl)dibenzene (24) 1H NMR (500 MHz, CDCl3) δ ppm: 3.93
(d, J = 7.9 Hz, 2H), 6.15 (t, J = 7.9 Hz, 1H), 6.67 (d, J = 7.6 Hz, 2H), 7.16 (m, 2H), 7.23 (t, J =
7.6 Hz, 2H), 7.27 (m, 4H), 7.51 (t, J = 7.6 Hz, 2H), 7.64 (t, J = 7.6 Hz, 1H), 7.80 (d, J = 7.6 Hz,
2H). 13C NMR (100 MHz, CDCl3) δ ppm: 57.5, 114.0, 127.4, 127.8, 128.2, 128.3, 128.4, 128.5,
129.1, 129.2, 130.1, 133.7, 137.7, 138.5, 140.7, 149.7. LRMS [ESI-MS +ve] calculated for
(C21H18O2S+Na): 357.1, observed: 357.1.
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3.1 Introduction
Cathepsin L is a prominent member of cysteine cathepsin family of enzymes whose
aberrant function has been linked to metastatic cancer83. Cathepsin L promotes metastatic
behavior by efficiently degrading and hydrolyzing various components of the extracellular
matrix (ECM), such as laminin, fibronectin, and collagen. Numerous studies strongly indicate
that cathepsin L activates signaling pathways that drive invasion in metastatic cancer45b, 131. Its
inhibition in invasive cancer is considered an attractive strategy for anti-cancer drug
development.
Despite the linkage of cathepsin L to metastatic cancer, its functions in appropriate
cellular contexts also remain largely unknown. Although it is generally believed that in normal
cells cathepsin L is endosomal or lysosomal, nuclear and cytosolic roles have also recently
emerged in other cells37, 132. In addition, numerous contradictory roles of cathepsin L have been
reported. For example, in glioblastoma nuclear cathepsin L activity is involved in regulating the
activity of transcription factors in a manner that promotes aberrant proliferation133. In contrast, a
pro-apoptotic role was attributed to cytosolic cathepsin L in human glioma cells134. In the context
of bone tissues, cathepsin L seems to be involved in both bone growth135 and bone loss
processes136. Such examples suggest that the underlying role of cathepsin L depends on its
activation level in distinct cell-types and its specific microenvironment. Determination of the
cellular level of activated cathepsin L would require a cell-active, potent and selective small
molecule probe. In recent years, activity-based probes have emerged as powerful tools for such
tasks137. Acquisition of a suitable activity-based cathepsin L probe however requires that first a
small molecule inhibitor be developed that (a) is cell-permeable, (b) inhibits cathepsin L activity
potently and selectively, (c) utilizes a covalent irreversible chemistry for inhibition, and (d) is
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non-basic in nature. The property of being non-basic is especially important for homogenous
distribution of probe in cell or else an undesired accumulation (and thus non-selective inhibition
of other cysteine cathepsins) will occur in the acidic environment of the lysosome138. While
several potent and reversible modulators of cathepsin L activity exist, only a few irreversible
inactivating agents have been reported so far; none of which are suitable for development of a
cell-active activity-based cathepsin L probe. In this study, using a hybrid-design approach, the
development of a highly potent, selective, non-basic, and active-site directed irreversible
inhibitor (KD-1, Figure 3.1) of cathepsin L activity is reported.

3.2 Rationale
The active site architecture of cathepsin L includes substrate binding cavities made of
both non-prime and prime site pockets, arranged on two sides of the scissile amide bond27. The
molecular framework of a cathepsin L-specific inhibitor was conceptualized so that the
functional groups occupied both the regular non-prime site (i.e. S1, S2, S3) and the prime site
(S′) binding pockets. Earlier studies involving x-ray crystallography indicated that the S′ pocket
of cathepsin L could provide a strategic site for designing a selective and potent inhibitor139. A
visual analysis of a covalent and reversible inhibitor, Z-Phe-Tyr-(O-tert Bu)-C(O)CHO, bound to
cathepsin L indicated that a non-polar cluster from the S′ pocket, involving Trp189, Leu144,
Ala138, and Gly139 residues, formed critically important binding interactions with the tert-butyl
group.139b In another related study, it was noted that an aromatic moiety suitably placed could
perhaps form more effective inhibitory interactions with the S′ residues of cathepsin L.140 Thus,
we sought to first screen for a ligand that would contain an electrophilic warhead and a
functionalized aromatic group suitable for interacting with the prime site residues. Although
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vinylsulfones have been utilized as an electrophilic warhead57, 141, the vinylsulfonate ester moiety
has not yet been explored for the development of a covalent and irreversible inhibitor of
cathepsin L. This was perhaps surprising since it was carefully noted that vinylsulfonate ester
moiety displays a far superior reactivity as a Michael acceptor than vinyl sulfones (and
sulfonamides)142. In addition, we surmised that an additional S-O bond present in vinylsulfonate
(but not in vinylsulfone) could place the functionalized aryl group into the S′ pocket for optimal
interaction. To test this hypothesis for cathepsin L inhibition, the inhibitory potency of phenyl
vinylsulfonate and phenyl vinylsulfone towards cathepsin L was determined. As anticipated,
phenyl vinylsulfonate exhibited 3-fold better potency than phenyl vinylsulfone under identical
Synthesize a library of aryl
vinylsulfonates, screen, and
identify the lead inhibitory
compound that targets
-site (S’) binding pocket
prime

1

KD-1
Cbz-Leu-Phe-CONH2
Figure 3.1. A hybrid-design approach in the development of a highly potent time-dependent
inhibitor (KD-1) of human cathepsin L. To generate KD-1, a competitive inhibitor CBZ-PheLeu-CONH2 of modest potency (Ki=14 µM), known to target S1, S2, and S3 pockets of
cathepsin L, is conjugated to a prime site (S’)-targeting inhibitory ligand 1 at its C-terminal.
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experimental conditions (data not shown). This finding strengthened the possibility that an
effective S′-targeting ligand could be constructed. Thus a focused library of aryl vinylsulfonate
ester compounds was synthesized and screened against cathepsin L (see experimental section).
This screen identified 4-bromophenyl vinylsulfonate ester (Figure 3.1, Compound 1) as the most
effective lead aryl vinylsulfonate ligand.
Torkar et al.58 recently reported Cbz-Phe-Leu-CONH2 (Figure 3.1A) as a modest
inhibitor (Ki = 14 µM) of cathepsin L. This compound is non-basic and inhibits cathepsin L
activity by presumably occupying the non-prime pockets (i.e. S1, S2, and S3). We hypothesized
that a hybrid design that incorporated the key features of 1 and Cbz-Phe-Leu-CONH2 could
render a highly potent and selective inhibitor of cathepsin L. Thus KD-1 was conceived (Figure
3.1) and synthesized.

3.3 Chemistry
KD-1 was synthesized according to scheme 3.1. Oxidation of N-Boc-L-Leucinol lead to
corresponding aldehyde which was utilized for the next step without any further purification 143.
Wittig intermediate (II) was synthesized from ethyl methanesulfonate by treating with
butyllithium followed by addition of diethyl chlorophosphate in anhydrous THF under inert
condition144. Treatment of intermediate II with sodium hydride followed by addition of N-BocL-Leucinal (II) in anhydrous THF under inert condition yielded Boc-protected leucine
vinylsulfonates (III). Deprotection of Boc group was carried out by treating intermediate III with
25% TFA in DCM. The free amine thus obtained was coupled to commercially available Cbzprotected phenylalanine to generate intermediate IV. Treatment of IV with tetrabutyl ammonium
iodide in acetone led to sulfonate salt which was utilized for the next step without any further
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purification. The sulfonate salt, thus obtained, was converted to sulfonyl chloride by treating

Scheme 3.1: Synthetic route utilized in the development of cathepsin L inhibitor, KD-1.
with sulfuryl chloride in presence of triphenylphosphine. The intermediate sulfonyl chloride was
treated with 4-bromo phenol in presence of triethyl amine to obtain final compound KD-1.

3.4 Results and Discussion
To get an estimate of potency, an experiment was performed to obtain the IC50 value. As
anticipated, a highly potent inhibition was observed (IC50 = 3.6 ± 0.1 nM). Since the IC50 value is
not an accurate indicator of potency of a time-dependent inhibitor, a dose-dependent experiment
was performed at various inhibitor concentrations and the progress curves were recorded under
pseudo-first order conditions (i.e. [KD-1]>>[Cat. L]) (Figure 3.2). Analysis of the progress
curves58 revealed near diffusion-controlled inactivation kinetics (second order inactivation rate
constant (kinact) = 4.3 x 106 M-1s-1). The mode of inhibition was irreversible in nature because
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enzyme activity could not be recovered, even after a very large dilution of the inactivated
reaction mixture (data not shown).

Figure 3.2. Time-dependent inhibition of human cathepsin L by KD-1. Progress
curves for cathepsin L-catalyzed hydrolysis of fluorescent substrate, Z-Phe-Arg-(7amino-4-methylcoumarin, in the absence and presence of appropriate concentration of
KD-1.
The selectivity of KD-1 towards cathepsin L enzyme was assessed next. To demonstrate
this, a panel of recombinant proteases and phosphatases were evaluated for their inhibition using
steady-state inhibition assays. This panel of enzymes included cysteine cathepsins, an aspartyl
cathepsin, a serine cathepsin, a cysteine containing enzyme PTP, and a serine protease. The
second order inactivation rate constants were thus determined by performing inactivation
kinetics under a pseudo-first order condition, as described before94 (Table 3.1). In the panel of
enzymes tested, KD-1 displayed a remarkable selectivity towards cathepsin L.

79

Table 3.1. Second order enzyme inactivation rate constants (kinact) of cathepsin L inhibitor KD-1
against a panel of closely-related enzymes.

Enzyme Family

Cysteine Cathepsins

Aspartyl Cathepsin
Serine Cathepsin

Enzyme

kinact (M-1s-1)

RSF

Cathepsin L

4.3x106

1

Cathepsin K

4.4x104

100

Cathepsin B

96

44,000

Cathepsin S

3.5x105

13

Cathepsin H

NI

Cathepsin D

NI

NA**

NI*

NA**

Cathepsin G

NA**

Protein Tyrosine Phosphatase

hptp1b

NI*

NA**

Serine Protease

Trypsin

NI*

NA**

Relative Selectivity Factor (RSF) = kinact (Cathepsin L) / kinact (Other enzyme); NI* = No
Inhibition at 0.1 mM of KD-1 in 1 h; NA** = Not Applicable.

While a 13- and 100-fold selectivity was observed against most closely homologous cysteine
cathepsins S and K respectively, a very high selectivity (44,000 fold) was observed against
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cysteine cathepsin B. Furthermore, no reactivity was observed against other panel of enzymes
(e.g. aspartyl cathepsin D, serine cathepsin G, and a low pKa cysteine containing enzyme
hPTP1B, and serine protease trypsin). A remarkable selectivity profile observed for KD-1 in
these experiments is noteworthy and should bode well for biological applications.
The ability of KD-1 to decrease the activity of cathepsin L towards collagen type I, a
physiological substrate of cathepsin L, was investigated next145. As expected, KD-1 protected the
degradation of human collagen type I by cathepsin L in vitro (Figure 3.2A). To further
demonstrate that KD-1 was cell permeable and therefore suitable for use in biological contexts,
an experiment involving metastatic breast cancer MDA-MB-231 cells was performed. This cell
line is known to overexpress cathepsin L146, thereby promoting invasion. A cell-permeable
fluorescent substrate of cathepsin L, Z-Phe-Arg-(7-amino-4-methylcoumarin, was utilized to
assess the intracellular inhibitory efficacy of KD-1. A near complete loss of intracellular
substrate turnover (as indicated by loss of green fluorescence) was evident in KD-1-treated cells,
compared to control (Figure 3.2B). This experiment demonstrated that KD-1 was indeed cell
permeable and was able to successfully block cathepsin L activity in intact cells. To the best of
our knowledge this is the first example where an inhibitor developed against cathepsin L is (i)
highly potent and selective (ii) non-basic (iii) hydrolytically stable, and most importantly (iv) cell
active. Such desirable traits are anticipated to lend themselves well in delineating precise roles of
cathepsin L biology in specific tissue-types, and the development of a selective activity-based
cathepsin L probe.
Finally, the functional effect of KD-1 on migratory behavior of highly metastatic MDAMB-231 cells was investigated using a wound-healing assay. The metastatic cells are highly
motile because E–cadherin, an important adhesive protein of cell-cell junctions, is a proteolytic
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Figure 3.3: [A] Inhibitor KD-1 protects a physiological substrate of cathepsin L,
human collagen type I, from proteolytic degradation in vitro. The α, β, and γ bands
of collagen I are shown by blue arrows (left) [B] Effect of KD-1 on cathepsin L
activity in a metastatic breast cancer cell line. MDA-MB-231 cells were incubated
with (a) vehicle (DMSO 0.05%), and (b) KD-1 (750 nM) overnight (22 hrs).
Intracellular inhibition of cathepsin L activity was assessed by exposing the cell to a
cell-permeable fluorogenic substrate, Z-Phe-Arg-(7-amino-4-methylcoumarin)
(2 minutes). The signal intensity (green) that emergesfrom the enzymatic turnover
of the fluorophore substrate (white arrow) is lost when inhibitor KD-1 is present.
This experiment demonstrates that KD-1 is cell permeable, and is inhibiting
intracellular cathepsin L activity in these cells. The results are representative of 3
independent experiments. Scale bar = 25 μm.
target of overabundant cathepsin L43. Most cancer cells lose E-cadherin function as they become
migratory, and hence metastatic. When MDA-MB-231 cells were treated with KD-1 (compared
with DMSO-treated control cells) and the wound-healing assay was initiated, it was observed
that cell motility decreased in KD-1-treated cells, compared to control (Figure 3.4). This result is
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consistent with cellular inhibition of cathepsin L by KD-1 since an enhanced integrity of cell-cell
junctions is expected in these cells due to maintenance of appropriate levels of E-cadherin.
Further experiments are currently being planned to systematically investigate the effect of KD-1
on other invasive cancer cell types.

3.5 Conclusions
Using a hybrid-design approach and employing a vinylsulfonate ester functionality, a
highly potent and selective cathepsin L inhibitory agent KD-1 has been developed. KD-1
successfully blocks intracellular cathepsin L activity in intact cells, and possesses anti-migratory
potential. It is anticipated that KD-1 will find extensive applications in probing the
undocumented roles of cathepsin L in diverse cellular microenvironments and human diseases.147
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Control (DMSO) KD-1(750 nM)

B
*

% Wound Closure

A

t=0
hr.

t = 22
hrs.

DMSO

KD-1

Figure 3.4. [A] KD-1 reduces migratory potential of highly metastatic MDA-MB-231
Breast cancer cells, as assessed by the wound healing assays. MDA-MB-231 cells were
grown overnight in a 6-well plastic dish before treating with DMSO (control, 0.05%) or KD-1
(750 nM). After creating the wounds by drawing a pipet across a confluent field of cells,
images were acquired at 0 h and 22 h. Representative images of three independent
experiments are shown here. The dotted yellow lines indicate the edge of the wound at time
zero, and the height of the yellow arrows are indicative of wound width. [B] The wound
closure, a direct measurement of cell migratory potential, was calculated using the following
equation: % Wound Closure = [(A0 – A22)/A0] × 100%, where A0 is the area of the wound
measured immediately after the scratch, and A22 is the area of the wound after 22 h.
The figure represents a statistical analysis from 3 independent experiments using the
unpaired Student’s t test (*, p<0.0001). The data were evaluated as the mean +1 standard
deviation. The image analysis was performed by ImageJ software.

84

3.6 Experimental
3.6.1 Synthesis
General:

1

H NMR spectra were recorded at either 400 or 500 MHz using CDCl 3 or DMSO

as the solvent. 13C NMR spectra were recorded at either 125 or 100 MHz using CDCl3 or DMSO
as the solvent. Chemical shifts (δ) are reported in parts per million (ppm) and referenced to
CDCl3 (7.26 ppm for 1H and 77.0 ppm for 13C), DMSO (2.50 ppm for 1H and 39.5 ppm for 13C).
Coupling constants (J) are reported in Hertz (Hz) and multiplicities are abbreviated as singlet (s),
doublet (d), doublet of doublets (dd), triplet (t), triplet of doublets (td), and multiplet (m). The
mass spectra were acquired using a 6520 Accurate-Mass Quadrupole Time-of-Flight (Q-TOF)
LC/MS (Agilent Technologies, Santa Clara, CA, USA). 4-ethynylbenzyl alcohol was purchased
from Santa Cruz Biotechnology, Inc. (Dallas, Texas, USA). O-(1H-6-Chlorobenzotriazole-1-yl)1,1,3,3-tetramethyluronium hexafluorophosphate (HCTU) was purchased from peptide
international (Louisville, Kentucky, USA). All anhydrous solvents were purchased from SigmaAldrich (St. Louis, MO, USA). All other materials were purchased from Fisher Scientific Inc.
(Pittsburgh, PA, USA).
Synthesis of library of aryl vinylsulfonate ester compounds (1-27):
Synthesis of all aryl vinylsulfonates were carried out using a literature reported protocol
148

.

4-Bromophenyl ethenesulfonate (1): Pale yellow semi solid. Rf = 0.46. Hexane: EtOAc (8:2).
Yield: 61%.1H NMR (400 MHz CDCl3) δ ppm: 6.19 (d, J = 10.0Hz, 1H), 6.36 (d, J = 15.1Hz,
1H), 6.67 (dd, J = 15.1Hz, 10.0Hz, 1H), 7.12 (d, J = 10.2Hz, 2H), 7.50 (d, J = 10.2Hz, 2H). 13C
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NMR (100 MHz CDCl3) δ ppm: 120.9, 123.7 131.7, 132.3, 133.0, 148.3. HRMS [ESI-MS +ve]
calculated for (C8H7BrO3S+H)+: 262.9378, observed: 262.9375.
Quinoline-8-yl ethenesulfonate (2): Colorless solid Rf = 0.21.Hexane: EtOAc (8:2). Yield: 65%.
1

H NMR (400MHz, CDCl3) δ ppm: 6.05 (d, J= 10.2Hz, 1H), 6.35 (d, J= 15.1Hz, 1H), 7.11 (dd,

J= 15.1Hz and 10.2Hz, 1H), 7.50 (dd, J= 5.2Hz and 5.3Hz, 1H), 7.56 (m, 1H), 7.72 (d, J= 5.3Hz,
1H), 7.81 (d, J= 5.3Hz, 1H), 8.25 (d, J= 5.3Hz, 1H), 8.98 (s, 1H). 13C NMR (100MHz, CDCl3) δ
ppm: 122.1, 123.3, 126.2, 127.2, 129.7, 130.2, 133.4, 136.1, 141.3, 145.3, 150.9. HRMS [ESIMS +ve] calculated for (C11H9NO3S+H)+: 236.0376, observed: 236.0375.
5-Nitroquinoline-8-yl ethenesulfonate (3): Colorless solid. Rf = 0.24. Hexane: EtOAc (8:2).
Yield: 68%. 1H NMR (400MHz, CDCl3) δ ppm: 6.15 (d, J= 8.2Hz, 1H), 6.45 (d, J= 16.1Hz,
1H), 7.11, (dd, J= 16.1Hz and 8.2Hz, 1H), 7.74 (dd, J= 4.1Hz and 8.2Hz, 1H), 7.83 (d, J= 8.5Hz,
1H), 8.44 (d, J= 8.5Hz, 1H), 9.07 (d, J= 8.3Hz, 1H), 9.11 (d, J= 4.1Hz, 1H). 13C NMR (100MHz,
CDCl3) δ ppm: 121.5, 122.9, 124.8, 124.9, 131.3, 132.4, 133.2, 141.2, 143.7, 149.7, 151.9.
HRMS [ESI-MS +ve] calculated for (C11H8N2O5S+H)+: 281.0227, observed: 281.0227 .
[1, 1’-Biphenyl]-4-yl ethenesulfonate (4): white powder. Rf = 0.28. Hexane: EtOAc (9:1). Yield:
76%. 1H NMR (400MHz, CDCl3) δ ppm: 6.19 (d, J= 10.1Hz, 1H), 6.41 (d, J= 16.6Hz, 1H), 6.70
(dd, J= 10.1Hz and 16.6Hz, 1H), 7.30 (m, 2H), 7.33-7.47 (m, 3H), 7.57 (m, 4H).

13

C NMR

(100MHz, CDCl3) δ ppm: 122.6, 127.1, 127.8, 128.5, 128.9, 131.8, 132.1, 139.8, 140.6, 148.7.
HRMS [ESI-MS +ve] calculated for (C14H12O3S+Na)+: 283.0399, observed: 283.0399.
4’-Nitro-[1, 1’-biphenyl]-4-yl ethenesulfonate (5): yellow powder. Rf = 0.25. Hexane: EtOAc
(8:2). Yield: 72%. 1H NMR (400MHz, DMSO-D6) δ ppm: 6.35 (d, J= 16.8Hz, 1H), 6.43 (d, J=
10.1 Hz, 1H), 7.30 (dd, J= 10.1Hz and 16.8Hz, 1H), 7.46 (d, J= 8.7Hz, 2H), 7.90 (d, J= 8.5Hz,
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2H), 7.98 (d, J= 8.7Hz, 2H), 8.32 (d, J= 8.7Hz, 2H).

13

C NMR (100MHz, DMSO-D6) δ ppm:

123.1, 124.1, 128.0, 129.1, 132.2, 133.6, 136.9, 145.1, 146.9, 149.5. HRMS [ESI-MS +ve]
calculated for (C14H11NO5S+H): 328.0250, observed: 328.0247.
Methyl 2-((vinylsulfonyl) oxy) benzoate (6): Viscous liquid Rf = 0.51. Hexane: EtOAc (8:2).
Yield: 67%. 1H NMR (500MHz, CDCl3) δ ppm: 3.93 (s, 3H), 6.16 (d, J= 10.1Hz, 1H), 6.37 (d,
J= 14.9Hz, 1H), 6.82 (dd, J= 14.91Hz and 10.1Hz, 1H), 7.39 (m, 2H), 7.57 (t, J= 10.4Hz, 1H),
7.97 (d, J= 10.4Hz, 1H).

13

C NMR (100MHz, CDCl3) δ ppm: 52.5, 124.1, 124.8, 127.2, 131.3,

132.1, 132.7, 133.7, 147.8, 164.9. HRMS [ESI-MS +ve] calculated for (C10H10O5S+Na)+:
265.0141, observed: 265.0141.
Methyl 4-((vinylsulfonyl) oxy) benzoate (7): white powder. Rf = 0.59. Hexane: EtOAc (8:2).
Yield: 62%. 1H NMR (400MHz, CDCl3) δ ppm: 3.92 (s, 3H), 6.23 (d, J= 10.2Hz, 1H), 6.39 (d,
J= 14.9Hz, 1H), 6.73 (dd, J= 14.9Hz and 10.2Hz, 1H), 7.31 (d, J= 10.1 Hz, 2H), 8.08 (d, J=
10.1Hz, 2H). 13C NMR (100MHz, CDCl3) δ ppm: 52.4, 122.2, 129.2, 131.5, 131.9, 132.3, 152.6,
165.9. HRMS [ESI-MS +ve] calculated for (C10H10O5S+H)+: 243.0322, observed: 243.0322.
4-Cyanophenyl ethenesulfonate (8): Yellow powder. Rf = 0.20. Hexane: EtOAc (9:1). Yield:
73%. 1H NMR (400MHz, CDCl3) δ ppm: 6.25 (d, J= 9.9Hz, 1H), 6.43 (d, J= 16.6Hz, 1H), 6.70
(dd, J= 16.6Hz and 9.9Hz, 1H), 7.37 (d, J= 8.7Hz, 2H), 7.72 (d, J= 8.6Hz, 2H).

13

C NMR

(100MHz, CDCl3) δ ppm: 111.4, 117.6, 123.3, 131.8, 132.7, 134.1, 152.2. HRMS [ESI-MS +ve]
calculated for (C9H7NO3S+H): 210.0219, observed: 210.0221.
4-Nitrophenyl ethenesulfonate (9): white powder. Rf = 0.49. Hexane: EtOAc (8:2). Yield: 69%.
1

H NMR (500MHz, CDCl3) δ ppm: 6.30 (d, J= 9.7Hz, 1H), 6.46 (d, J= 14.8Hz, 1H), 6.74 (dd, J=

14.8Hz and 9.7Hz, 1H), 7.44 (d, J= 9.8Hz, 2H), 8.30 (d, J= 9.8Hz, 2H).
87

13

C NMR (125MHz,

CDCl3) δ ppm: 123.1, 125.6, 131.5, 133.2, 146.3, 153.5. HRMS [ESI-MS +ve] calculated for
(C8H7NO5S+H)+: 230.0118, observed: 230.0118.
5-Fluoro-2-nitrophenyl ethenesulfonate (10): yellow viscous liquid. Rf = 0.29. Hexane: EtOAc
(9:1). Yield: 56%.1H NMR (400Hz, CDCl3) δ ppm: 6.27 (d, J= 9.6 Hz, 1H), 6.52 (d, J= 15.8 Hz,
1H), 6.76 (dd, J= 15.8 Hz and 9.6 Hz, 1Hz), 7.23 (m,1H), 7.31 (m, 1H), 8.17 (m, 1H). 13C NMR
(100MHz, CDCl3) δ ppm: 113.5 (d, JC-F= 26.1 Hz), 115.0 (d, JC-F= 23.2 Hz), 128.1 (d, JC-F= 10.1
Hz), 132.1, 133.2, 139.0, 143.8, 165.3 (d, JC-F= 258.2 Hz).HRMS [ESI-MS +ve] calculated for
(C8H6FNO5S+Na)+: 269.9843, observed: 269.9841.
4-Chlorophenyl ethenesulfonate (11): pale yellow viscous liquid. Rf = 0.27 Hexane: EtOAc (9:1).
Yield: 68%. 1H NMR (400MHz, CDCl3) δ ppm: 6.21 (d, J= 9.9Hz, 1H), 6.39 (d, J= 16.7Hz, 1H),
6.67 (dd, J= 16.7Hz and 9.9Hz, 1H), 7.19 (d, J= 9.0, 2H), 7.36 (d, J= 9.0, 2H).

13

C NMR

(100MHz, CDCl3) δ ppm: 123.7, 129.9, 131.7, 132.3, 133.1, 147.7. HRMS [ESI-MS +ve]
calculated for (C8H7ClO3S+H)+: 218.9877, observed: 218.9877.
2-Chlorophenyl ethenesulfonate (12): pale yellow viscous liquid. Rf = 0.25. Hexane: EtOAc
(9.5:0.5). Yield: 68%. 1H NMR (400MHz, CDCl3) δ ppm: 6.18 (d, J= 10.4Hz, 1H), 6.37 (d, J=
16.6Hz, 1H), 6.78 (dd, J= 16.6Hz and 10.4Hz, 1H), 7.25 (t, J= 7.7Hz, 1H), 7.30 (t, J= 7.7Hz,
1H), 7.42 (d, J= 8.1Hz, 1H), 7.44 (d, J= 8.1Hz, 1H). 13C NMR (100MHz, CDCl3) δ ppm: 124.5,
127.1, 128.1, 128.2, 130.9, 131.8, 132.4, 145.3. HRMS [ESI-MS +ve] calculated for
(C8H7ClO3S+Na)+: 240.9697, observed: 240.9699.
3-Chlorophenyl ethenesulfonate (13): colorless viscous liquid. Rf = 0.25 Hexane: EtOAc
(9.5:0.5). Yield: 70%. 1H NMR (400MHz, CDCl3) δ ppm: 6.21 (d, J= 9.9Hz, 1H), 6.40 (d, J=
16.7Hz, 1H), 6.67 (dd, J= 16.7Hz and 9.9Hz, 1H), 7.16 (m, 1H), 7.26 (m, 1H), 7.31 (m, 2H). 13C
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NMR (100MHz, CDCl3) δ ppm: 120.6, 122.8, 127.7, 130.6, 131.8, 132.3, 135.1, 149.6. HRMS
[ESI-MS +ve] calculated for (C8H7ClO3S+H)+: 218.9877, observed: 218.9877.
4-Chloro-2-fluorophenyl ethenesulfonate (14): colorless viscous liquid. Rf = 0.48

Hexane:

EtOAc (8:2). Yield: 63%.1H NMR (400MHz, CDCl3) δ ppm: 6.22 (d, J= 10.0Hz, 1H), 6.39 (d,
J= 16.6Hz, 1H), 6.72 (d, J= 16.6Hz and 10.0Hz, 1H), 7.21 (m, 2H), 7.34 (m, 1H).

13

C NMR

(100MHz, CDCl3) δ ppm: 117.9 (d, JC-F= 21.1 Hz, 1C), 125.2 (d, JC-F= 3.6 Hz, 1C), 125.8,
131.7, 132.4, 133.5 (d, JC-F= 8.8 Hz, 1C), 135.4 (d, JC-F= 12.6 Hz, 1C), 154.1 (d, JC-F= 250.1 Hz,
1C).HRMS [ESI-MS +ve] calculated for (C8H6ClFO3S+Na)+: 258.9602, observed: 258.9604.
4-Chloro-3-fluorophenyl ethenesulfonate (15): colorless viscous liquid. Rf = Hexane: EtOAc
(9:1). Yield: 64%. 1H NMR (400MHz, CDCl3) δ ppm: 6.25 (d, J=9.9 Hz, 1H), 6.41 (d, J=16.6
Hz, 1H), 6.68 (dd, J= 16.6 Hz and 9.9 Hz, 1H), 7.01 (m, 1H), 7.12 (m, 1H), 7.43 (m, 1H).

13

C

NMR (100MHz, CDCl3) δ ppm: 111.6 (d, JC-F= 24.2 Hz) 119.0 (d, JC-F= 4.1 Hz) 120.3 (d, JC-F=
17.7 Hz) 131.1, 131.6, 132.8, 148.2 (d, JC-F= 9.3 Hz,), 158.0 (d, JC-F= 251.8 Hz) HRMS [ESI-MS
+ve] calculated for (C8H6ClFO3S+H)+: 236.9783, observed: 236.9783.
4-Chloro-3-(trifluoromethyl) phenyl ethenesulfonate (16): colorless viscous liquid. Rf = 0.32.
Hexane: EtOAc (9:1). Yield: 57%. 1H NMR (400MHz, CDCl3) δ ppm: 6.27 (d, J= 9.8Hz, 1H),
6.42 (d, J= 16.6Hz, 1H), 6.71 (d, J= 16.6Hz and 9.8Hz, 1H), 7.40 (m, 1H), 7.55 (m, 2H).

13

C

NMR (100MHz, CDCl3) δ ppm: 121.7 (q, JC-F= 121.9 Hz), 122.2 (q, JC-F= 270.1 Hz), 126.9,
131.1, 132.5, 133.0, 133.1, 147.3 HRMS [ESI-MS +ve] calculated for (C9H6ClF3O3S+Na)+:
308.9570, observed: 308.9572.
4-Chloro-2, 3, 5, 6-tetrafluorophenyl ethenesulfonate (17): colorless liquid. Rf = 0.24 Hexane:
EtOAc (9.8:0.2). Yield: 66%. 1H NMR (400MHz, CDCl3) δ ppm: 6.35 (d, J= 9.9Hz, 1H), 6.56
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(d, J= 16.5Hz, 1H), 6.81 (dd, J= 16.5Hz and 9.9Hz, 1H).
131.8,

133.1,

140.3,

143.1,

143.2,

145.6

13

HRMS

C NMR (100MHz, CDCl3) δ ppm:
[ESI-MS

+ve]

calculated

for

(C8H3ClF4O3S+Na)+: 312.9320, observed: 312.9323.
4-Chloro-3-methylphenyl ethenesulfonate (18): colorless viscous liquid. Rf = 0.32. Hexane:
EtOAc (9:1). Yield: 80%. 1H NMR (400MHz, CDCl3) δ ppm: 2.35 (s, 3H), 6.19 (d, J= 10.3Hz,
1H), 6.35 (d, J= 16.7Hz, 1H), 6.68 (dd, J= 10.3Hz and 16.7 Hz, 1H), 7.00 (dd, J= 2.9Hz and 8.8
Hz, 1H), 7.10 (d, J= 2.8Hz, 1H), 7.30 (d, J= 8.6Hz, 1H).

13

C NMR (100MHz, CDCl3) δ ppm:

20.2, 120.9, 124.6, 130.1, 131.8, 132.3, 133.1, 138.1, 147.6. HRMS [ESI-MS +ve] calculated for
(C9H9ClO3S+Na)+: 254.9853, observed: 254.9855.
4-Chloro-3, 5-dimethylphenyl ethenesulfonate (19): white powder. Rf = 0.43. Hexane: EtOAc
(8:2). Yield: 59%. 1H NMR (500MHz, CDCl3) δ ppm: 2.27 (s, 6H), 6.10 (d, J= 5.5Hz, 1H), 6.28
(d, J= 20.0Hz, 1H), 6.59 (dd, J= 20.0Hz and 5.5Hz, 1H), 6.87 (s, 2H).

13

C NMR (100MHz,

CDCl3) δ ppm: 20.8, 121.8, 131.9, 132.1, 133.3, 138.6, 146.9 HRMS [ESI-MS +ve] calculated
for (C10H11ClO3S+Na)+: 269.0010, observed: 269.0010.
4-Chloro-2-nitrophenyl ethenesulfonate (20): pale yellow viscous liquid. Rf = 0.24 Hexane:
EtOAc (9:1). Yield: 72%. 1H NMR (400MHz, CDCl3) δ ppm: 6.29 (d, J= 9.9Hz, 1H), 6.49 (d, J=
16.7Hz, 1H), 6.81 (dd, J= 16.7Hz and 9.9Hz, 1H), 7.52 (d, J= 8.9, 1H), 7.65 (dd, J= 8.9Hz and
2.5Hz, 1H), 8.01 (d, J= 2.5Hz, 1H).

13

C NMR (100MHz, CDCl3) δ ppm: 126.1, 126.7, 131.9,

133.1, 133.4, 134.5, 139.8, 142.5. HRMS [ESI-MS +ve] calculated for (C8H6ClNO5S+Na)+:
285.9547, observed: 285.9547.
3, 4-Dichlorophenyl ethenesulfonate (21): colorless viscous liquid. Rf

=

0.33. Hexane: EtOAc

(9:1). Yield: 67%. 1H NMR (400MHz, CDCl3) δ ppm: 6.25 (d, J= 9.9Hz, 1H), 6.41 (d, J=
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16.6Hz, 1H), 6.68 (dd, J= 16.6Hz and 9.9Hz, 1H), 7.12 (dd, J= 8.8Hz and 2.7Hz, 1H), 7.39 (d,
J= 2.7Hz, 1H), 7.47 (d, J= 8.8Hz, 1H). 13C NMR (100MHz, CDCl3) δ ppm: 121.9, 124.5, 131.2,
131.5, 131.7, 132.8, 133.4, 147.6. HRMS [ESI-MS +ve] calculated for (C8H6Cl2O3S+H)+:
252.9487, observed: 252.9489.
2, 4, 5-Trichlorophenyl ethenesulfonate (22): white powder. Rf = 0.48 Hexane: EtOAc (8:2).
Yield: 59%. 1H NMR (400MHz, CDCl3) δ ppm: 6.26 (d, J= 8.5Hz, 1H), 6.45 (d, J= 16.1Hz, 1H),
6.77 (dd, J= 16.1Hz and 8.5Hz, 1H), 7.56 (s, 1H), 7.57 (s, 1H).

13

C NMR (100MHz, CDCl3) δ

ppm: 125.9, 126.3,131.4, 131.9, 132.1,132.7, 143.8. HRMS [ESI-MS +ve] calculated for
(C8H5Cl3O3S+H)+: 286.9098, observed: 286.9101.
2, 4, 6-Trichlorophenyl ethenesulfonate (23): white powder. Rf = 0.44 Hexane: EtOAc (9:1).
Yield: 63%. 1H NMR (400MHz, CDCl3) δ ppm: 6.26 (d, J= 10.3Hz, 1H), 6.56 (d, J= 16.5Hz,
1H), 6.94 (d, J= 16.5 Hz and 10.3Hz, 1H), 7.4 (s, 2H),
126.7,

128.3,

128.8,

130.6,

131.4,

139.5.

13

HRMS

C NMR (100MHz, CDCl3) δ ppm:
[ESI-MS

+ve]

calculated

for

(C8H5Cl3O3S+Na)+: 308.8917, observed: 308.8919.
Methyl 5-chloro-2-((vinylsulfonyl) oxy) benzoate (24): pale yellow viscous liquid. Rf = 0.23.
Hexane: EtOAc (9.5:0.5). Yield: 60%. 1H NMR (400MHz, CDCl3) δ ppm: 3.95 (s, 3H), 6.18 (d,
J= 10.0Hz, 1H), 6.37 (d, J= 16.7Hz, 1H), 6.81 (dd, J= 16.7Hz and 10.0Hz, 1H), 7.34 (d, J=
8.7Hz, 1H), 7.50 (d, J= 8.7Hz, 1H), 7.93 (s, 1H).

13

C NMR (100MHz, CDCl3) δ ppm: 52.7,

125.5, 126.1, 131.8, 132.4, 132.9, 133.5, 133.88, 146.2, 163.6. HRMS [ESI-MS +ve] calculated
for (C10H9ClO5S+Na)+: 298.9751, observed: 298.9751.
4-Fluorophenyl ethenesulfonate (25): colorless viscous liquid. Rf = 0.25. Hexane: EtOAc (9:1).
Yield: 69%. 1H NMR (400MHz, CDCl3) δ ppm: 6.10 (d, J= 10.0Hz, 1H), 6.37 (d, J= 16.7Hz,
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1H), 6.66 (dd, J= 10.0Hz and 16.7Hz, 1H), 7.10 (m, 2H), 7.22 (m, 2H).

13

C NMR (100 MHz,

CDCl3) δ ppm: 116.6 (d, JC-F= 29.0Hz,), 124.0 (d, JC-F= 9.2 Hz,), 131.8, 132.1, 145.1 (d, JC-F=
3.5Hz,), 161.7 (d, JC-F= 247.3Hz, 1C). HRMS [ESI-MS +ve] calculated for (C8H7FO3S+H)+:
203.0173, observed: 203.0174.
4-Iodophenyl ethenesulfonate (26): colorless viscous liquid. Rf = 0.29. Hexane: EtOAc (9:1).
Yield: 64%. 1H NMR (400MHz, CDCl3) δ ppm: 6.19 (d, J= 10.0Hz, 1H), 6.37 (d, J= 16.8Hz,
1H), 6.65 (dd, J= 16.8Hz and 10.0Hz, 1H), 6.99 (d, J= 8.7Hz, 2H), 7.70 (d, J= 8.7Hz, 2H). 13C
NMR (100MHz, CDCl3) δ ppm: 91.9, 124.4, 131.7, 132.3, 139.1, 149.2. HRMS [ESI-MS +ve]
calculated for (C8H7IO3S+Na)+: 332.9053, observed: 332.9056.
2-Ethylphenyl ethenesulfonate (27): pale yellow viscous liquid. Rf = 0.37. Hexane: EtOAc (9:1).
Yield: 64%. 1H NMR (400MHz, CDCl3) δ ppm: 1.22 (t, J= 7.6Hz, 3H), 2.71 (q, J= 7.6Hz, 2H),
6.14 (d, J= 9.9Hz, 1H), 6.38 (d, J= 16.6Hz, 1H), 6.72 (dd, J= 16.6Hz and 9.9Hz, 1H), 7.23 (m,
4H).13C NMR (100MHz, CDCl3) δ ppm: 14.2, 23.1, 121.9, 127.1, 127.4, 130.1, 131.2, 132.7,
137.0, 147.6. HRMS [ESI-MS +ve] calculated for (C10H12O3S+Na)+: 235.0399, observed:
235.0401.
The synthetic scheme utilized in the development of cathepsin L inhibitor KD-1
Inhibitor KD-1 was synthesized by following scheme 3.1
(i). Synthesis of ethyl (diethoxyphosphoryl)methanesulfonate (I). This compound was
synthesized by following the literature reported protocol144 and its characterization was found to
be consistent with the previously reported NMR spectra149.
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(ii) Synthesis of tert-butyl (4-methyl-1-oxopentan-2-yl)carbamate (II). This compound was
synthesized by following the literature reported protocol and its characterization was found to be
consistent with the previously reported NMR spectra 143.
(iii).Synthesis of ethyl (E)-3-((tert-butoxycarbonyl)amino)-5-methylhex-1-ene-1- sulfonate (III).
This compound was prepared using a literature reported protocol with appropriate
modification130 . A solution of ethyl (diethoxyphosphoryl)methanesulfonate (483 mg, 1.86
mmol, 1 equiv) in anhydrous tetrahydrofuran (4 mL) was added dropwise to a stirring suspension
of sodium hydride (58 mg, 2.41 mmol) in anhydrous tetrahydrofuran (3 mL) at 0°C under inert
condition. After 30 min, a solution of N-BOC-L-leucinal in anhydrous tetrahydrofuran (5 mL)
was added to the reaction mixture. Stirring was continued for an hour. The reaction was
quenched by an addition of 5 mL of saturated ammonium chloride solution. The solution was
concentrated under vacuum, diluted with water (10 mL), and extracted with ethylacetate (3×25
mL). The combined organic extracts were washed brine and dried over sodium sulfate, ﬁltered,
and concentrated under vacuum. Puriﬁcation by ﬂash column chromatography (silica gel; 90:10
hexane/ethylacetate) provided 419 mg (yield: 70%) of product. Rf = 0.6 (80:20
hexane/ethylacetate). 1H NMR (500 MHz, CDCl3) δ ppm: 0.94 (m, 6H), 1.37 (t, J= 6.9 Hz, 3H),
1.44 (s,11H), 1.70 (m,1H), 4.16 (q, J= 6.9 Hz, 2H), 4.37 (m,1H), 4.73 (m,1H), 6.31 (d, 15.2 Hz,
1H), 6.79 (dd, J= 15.2 and 5.4 Hz, 1H).

13

C NMR (125 MHz, CDCl3) δ ppm: 15.1, 22.0, 23.1,

24.8, 28.3, 43.4, 49.7, 67.3, 80.1, 124.4, 149.5, 155.3. HRMS [ESI-MS +ve] calculated for
(C14H27NO5S + Na)+: 344.1508, observed 344.1528.
(iv).

Synthesis

of

Ethyl

(E)-3-(2-(((benzyloxy)carbonyl)amino)-3-phenylpropanamido)-5-

methylhex-1-ene-1-sulfonate (IV)
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To a stirred solution of the BOC-protected amine III (180 mg, 0.56 mmol) was added
25% solution of trifluoroacetic acid in dichloromethane (5 ml) and stirred for 1 hr. The solution
was removed in vacuo. The residue was dissolved in DMF(2 ml). To this was added a cocktail of
N-Cbz-L-phenylalanine (168 mg, 0.56 mmol), HCTU (232mg, 0.56 mmol) and N,Ndiisopropylethylamine (375μl, 2.15 mmol) as a solution in anhydrous DMF (5 ml) at 0°C. Once
the addition was done, ice bath was removed and the reaction was stirred overnight. The reaction
was then diluted with 50 ml of ethyl acetate and washed with saturated ammonium chloride
solution (25 ml), saturated sodium bicarbonate solution, and with brine (25 ml). The organic
layer was dried over sodium sulfate and concentrated in vacuo. Puriﬁcation by ﬂash column
chromatography (silica gel; 80:20 hexane/ethylacetate) provided 169 mg (yield: 60%) of product.
Rf =0.21(80:20 hexane/ethylacetate). 1H NMR (400 MHz, CDCl3) δ ppm: 0.86 (m, 6H), 1.31 (m,
2H), 1.37 (t, J= 6.9 Hz, 3H), 1.51 (m,1H), 3.05 (dd, J= 14.4 and 7.7 Hz, 1H), 3.11 (dd, J= 14.4
and 6.4 Hz, 1H), 4.13 (m, 2H), 4.38 (m, 1H), 4.62 (m, 1H), 5.08 (m, 2H), 5.35 (bs, 1H), 5.94 (d,
15.4 Hz, 2H), 6.61 (dd, J= 15.4 and 5.2 Hz, 1H), 7.17 (m, 2H), 7.32 (m,8H).

13

C NMR (100

MHz, CDCl3) δ ppm: 14.9, 21.9, 22.7, 24.6, 38.2, 42.7, 48.0, 56.5, 67.0, 67.3, 124.5, 127.6,
128.2, 128.4, 128.6, 129.2, 129.2, 135.8, 135.9, 147.7, 156.1, 170.6. HRMS [ESI-MS +ve]
calculated for (C26H34N2O6S + H)+: 503.2217, observed 503.2218.
(v). Synthesis of 4-bromophenyl (E)-3-(2-(((benzyloxy)carbonyl)amino)-3-phenylpropanamido)5-methylhex-1-ene-1-sulfonate (KD-1)
This compound was prepared using a literature reported protocol with appropriate
modification 150. To a stirred solution of IV (150 mg, 0.3 mmol) in acetone was added tetrabutyl
ammonium iodide (45 mg, 0.3 mmol) and refluxed for overnight. The mixture was concentrated
in vacuo and was dissolved in anhydrous dichloromethane (2 ml). This was added to a stirred
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solution of triphenyl phosphine (157 mg, 0.6 mmol) and sulfuryl chloride (53 μl, 0.664 mmol) in
anhydrous dichloromethane (4 ml) at 0°C. Once the addition was done, ice bath was removed
and the reaction was stirred overnight. The mixture was then concentrated in vacuo and passed
through silica (oven dried) using hexane and ethyl acetate (90:10) to recover sulfonyl chloride as
white solid. Subsequently, the sulfonyl chloride (100mg, 0.23 mmol) was dissolved in anhydrous
dichloromethane (3 ml). 4-bromophenol (60 mg, 0.345 mmol) was added to the solution
followed by addition of triethylamine (100 μl, 0.69 mmol) at 0°C. The mixture was stirred for
one hr and diluted with ethyl acetate (30 ml) followed by washing with saturated ammonium
chloride solution (15 ml), saturated sodium bicarbonate solution (15ml ×3), and with brine (15
ml). The organic layer was dried over sodium sulfate and concentrated in vacuo. Puriﬁcation by
ﬂash column chromatography (silica gel; 90:10 hexane/ethylacetate) provided 40 mg (overall
yield: 22%) of the product as white solid. Rf =0.37 (80:20 hexane/ethylacetate). 1H NMR (400
MHz, CDCl3) δ ppm: 0.82 (m, 6H), 1.22 (m, 2H), 1.41 (m, 1H), 3.0 (dd, J= 13.7 and 7.9 Hz,
1H), 3.11 (dd, J= 13.7 and 6.4 Hz, 1H), 4.38 (m,1H), 4.52 (m, 1H), 5.07(m, 2H), 5.4 (bs,1H),
5.93(bs, 1H), 6.03(d, J=15.1 Hz, 1H), 6.46(dd, J= 15.1 and 5.2 Hz, 1H), 7.08 (m, 2H), 7.13 (m,
2H), 7.33 (m, 8H), 7.51 (m, 2H).

13

C NMR (100 MHz, CDCl3) δ ppm: 21.8, 22.5, 24.5, 38.3,

42.2, 48.2, 56.6, 67.4 120.8, 123.7, 124.5, 127.6, 128.2, 128.4, 128.6, 129.1, 129.1, 132.9, 135.8,
135.8, 148.3, 150.1, 156.1, 170.6. HRMS [ESI-MS +ve] calculated for (C30H33BrN2O6S +H)+:
629.1322, observed 629.1315.

3.6.2. Screening and Enzymology
General.

Following enzymes and their substrates were purchased from Enzo Life Sciences

(Farmingdale, NY, USA): cathepsin L (BML-SE201), cathepsin K (BML-SE553), cathepsin B
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(BML-SE198), cathepsin D (BML-SE199), cathepsin S (BML-SE453), cathepsin H (BMLSE200), cathepsin G (BML-SE283), human PTP1B (BML-SE332), Z-Arg-Arg-pNA (BMLP138), Z-Gly-Pro-Arg-AMC (BML-P142), Z-Phe-Arg-AMC (BML-P139), H-Arg-AMC.2HCl
(BML-P135), Suc-Ala-Ala-Pro-Phe-pNA (BML-P141), Mca-Gly-Lys-Pro-Ile-Leu-Phe-Phe-ArgLeu-Lys(Dnp)-D-Arg-NH2 (BML-P145), Z-Val-Val-Arg-AMC (BML-P199). N-alpha-BenzoylDL-arginine-p-nitroanilide (BAPNA) (B4875), trypsin (T1426), para-nitrophenylphosphate were
purchased from Sigma–Aldrich (St. Louis, MO, USA). All the biological grade buffers were
used and were purchased from Sigma–Aldrich (St. Louis, MO, USA). All enzyme kinetics
experiments (unless otherwise stated) were carried out at 30°C in appropriate buffer condition
with 5% DMSO concentration. For measuring the initial rates of enzyme catalyzed reaction, a
temperature-controlled steady-state arc lamp fluorometer equipped with Felix 32 software
(Photon Technology Instrument, Birmingham, NJ, USA) and a UV–Vis spectro-photometer
(Modelk25; Perkin Elmer Inc., Waltham, MA, USA) was used.
Screening of aryl vinylsulfonate library compounds:
The inactivation reaction of human liver cathepsin L (net 50 nM) by 10 μM of inhibitor
was performed under pseudo first order condition ([I]>>[E]) in a 0.5 ml eppendorf tube
maintained at 30°C in a temperature controlled bath. A previously reported cathepsin L assay
procedure was employed
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. Cathepsin L enzyme was first activated for 10 min in sodium

acetate buffer (400 mM, pH 5.5) containing 8 mM DTT and 4 mM Na2EDTA. The inactivation
reaction was initiated by the addition of inhibitor where DMSO concentration was maintained at
5%. After suitable time intervals, an aliquot of 8μl of incubation mixture was withdrawn and
added to an assay mixture (net assay volume 200μl) that contained 5 μM of Z-FR-AMC (Km=
2.2 μM) substrate at 30°C. A progress curve was recorded (excitation: 365 nm; emission: 440
96

nm) and the enzyme activity was determined by measuring the initial rates of substrate turnover
(Figure 3.5).

1 (95±3)

2 ( 9±1)

9 (90±2) 10 (5±2)

17 (80±7)

25 (32±3)

18 (82±2)

26 (85±3)

3 (57±3)

4 (87±5)

5 (70±4)

12 (17±2)

13 (32±3)

19 (46±5) 20 (29±1)

21 (56±4)

11 (31±5)

6 (34±4)

14 (74±4)

22 (26±3)

7 (87±2)

15 (64±4)

23 (29±7)

8 (88±3)

16 (69±5)

24 (4±2)

27 (12±2.5)

Figure 3.5. Chemical structures of the synthesized aryl vinylsulfonate library (1-27)
targeted for cathepsin L inhibition. Time-dependent inhibition experiments were
performed under pseudo-first order condition at 10 µM inhibitor concentration, as
described in the main text. In parenthesis, % inhibition is calculated from two
independent experiments.

Determination of IC50 of KD-1 against cathepsin L:
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Briefly IC50

,

experiment

was performed by subsequent
addition of active cathespsin L
(160 pM) and 5 μM of Z-FRAMC in acetate buffer (pH 5.5)
containing KD-1 (concentration
ranging from 0 pM to 15 nM) at
30°C. Net DMSO concentration
Figure 3.6. Dose response curve for KD-1 mediated
inhibition of human liver cathepsin L. The points are
experimental and the line joining them is the fit to
obtain the IC50 value as 3.6±0.1 nM.

was

maintained

reaction

at

was

8%.

The

monitored

fluorometrically (excitation: 365
nm; emission: 440 nm) for 100

seconds at 30°C. The experimental data thus obtained were plotted using SigmaPlot software and
fitted using Enzyme Kinetics module to obtain IC50 value. The IC50 value thus obtained was
3.6±0.1 nM (Figure 3.6).
Determination of kinetic inactivation parameters of KD-1 against cathepsin L:
The inactivation reaction of human liver cathepsin L (net 160 pM) by appropriate
concentrations of KD-1 was performed under pseudo first order condition ([I]>>[E]) in a
fluorescence quartz cuvette maintained at 30°C. Briefly, the inactivation reaction was performed
by subsequent addition of active cathespsin L (160 pM) and 5 μM of Z-FR-AMC in acetate
buffer (pH 5.5) containing KD-1 (concentration ranging from 1 nM to 20 nM). Net DMSO
concentration was maintained at 8%. The reaction was monitored fluorometrically (excitation:
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365 nm; emission: 440 nm) for 3 minutes at 30°C. Subsequently, the progress curves were
analyzed using non-linear regression according the following equation.58
P = vz [1- exp (-kobs* t)] / kobs;
where [P] is the product, vz is the initial velocity (at time zero), and kobs is the pseudo-first order
rate constant.
Pseudo-first order rate constants kobs were plotted against appropriate inhibitor
concentrations [I], and 2nd order inactivation rate constant kinact was calculated from the slope of
the plot according to following
equation 58 (Figure 3.7);
kobs = kinact [I] / [1+ ([S]/KM)]
where kobs is the pseudo-first order
rate constant, [I] is the inhibitor
concentration, [S] is the substrate
concentration, with a given KM

.

The data were analyzed using
KaleidaGraph (version 3.52).

Figure 3.7. Determination of second order inactivation
rate constant (kinact) for KD-1-mediated inhibition of
human liver cathepsin L. The kobs obtained from the
progress curve fit were plotted against appropriate
concentration of [KD-1]. The slope of the line yielded
the enzyme inactivation rate constant kinact.
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Selectivity profile of KD-1 against other enzymes
Determination of kinetic inactivation parameters of KD-1 against cathepsin S
A previously reported cathepsin S assay procedure was followed with suitable
modification
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. Thus, recombinant human cathepsin S enzyme was activated in the 100 mM

potassium phosphate buffer (pH 6.5) containing 2.5 mM DTT, 2.5 mM Na2EDTA for 10 min.
The inactivation reaction of cathepsin S (net 1 nM) by appropriate concentrations of KD-1 was
performed under pseudo first order condition ([I]>>[E]) in a fluorescence quartz cuvette
maintained at 30°C. Briefly, the inactivation reaction was initiated by subsequent addition of
active cathepsin L and 50 μM of Z-VVR-AMC (KM = 17.7 μM) in phosphate buffer (pH 6.5)
containing KD-1 (concentration ranging from 20 nM to 200 nM). Net DMSO concentration was
maintained at 8%.. The reaction was monitored fluorometrically (excitation: 365 nm; emission:
440 nm) for 3 minutes at 30°C. The progress curves were analyzed using the same equations
used for cathepsin L assay.
Cathepsin K inhibition assay
For assaying cathepsin K activity, a previously published protocol was followed with
appropriate modiﬁcation 153. Thus, recombinant human cathepsin K enzyme was activated in the
50 mM sodium acetate buffer (pH 5.5) containing 2.5 mM DTT, 2.5 mM Na2EDTA for 10 min.
The inactivation reaction of cathepsin K (net 50 nM) with inhibitor KD-1(250 nM) was initiated
under pseudo first order condition ([I]>>[E]). After suitable time intervals, an aliquot of 10 μl of
incubation mixture was withdrawn and the enzyme activity was monitored fluorometrically in
assay buffer (200 μl; 7.5% DMSO) containing 200 μM of Z-GPR-AMC (KM =68 μM; Ex/Em:
365/440 nm). The data thus obtained was plotted and fitted to the following equation:
100

At = Af – (Af – A0) exp (-kobs*t)
where At = enzyme activity at time t of cathepsin K inactivation, Af = final cathepsin K
activity at infinite time of inactivation, A0 = initial enzyme activity at zero time of inactivation,
and kobs = pseudo-first order rate constant of inactivation. The data were analyzed using
KaleidaGraph (version 3.52).
Cathepsin H inhibition assay
For assaying cathepsin H activity, a previously published protocol was followed with
appropriate modiﬁcation
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. Thus, human liver cathepsin H enzyme was activated in the 200

mM KH2PO4 / 200 mM Na2HPO4 buffer (pH 6.8) containing 5 mM DTT, 2 mM Na2EDTA for
10 min. The inactivation reaction of cathepsin H (net 330 nM) with inhibitor KD-1 (100 μM)
was initiated under pseudo first order condition ([I]>>[E]). After suitable time intervals, an
aliquot of 10 μl of incubation mixture was withdrawn and the enzyme activity was monitored
fluorometrically in assay buffer (200 μl; 8% DMSO) containing 300 μM of H-R-AMC.2HCl (KM
= 150 μM; Ex/Em: 365/440 nm).
*Assays involving cathepsin B, cathepsin D, cathepsin G, trypsin and PTP1B were carried out
according to the literature reported protocol 94.

3.6.3. Biological and Cell-Based Studies
Inhibition of Cathepsin L’s Collagenase Activity by KD-1
This experiment was carried out by following slight modification of a literature reported
protocol 154. Human skin type I collagen (Calbiochem) was dissolved in 100 mM acetic acid for
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24 h at room temperature to give a final concentration of 1.0 mg/ml. In 500 µl eppendorf tubes,
different concentrations of KD-1 (0 nM, 300 nM, 500 nM and 1000 nM) were incubated with
200 nM of active cathepsin L (Assay Condition: 100 mM sodium acetate pH 5.5, 1 mM EDTA, 3
mM DTT, 2% DMSO, 30°C) for 30 minutes. Reaction was initiated by addition of 6 µg of
collagen (Total reaction volume 26 µl). Reactions were quenched after 6 days by addition of 10
µl of Laemmli’s SDS- Sample Buffer (4X, reducing) and heated to 95°C for 10 minutes. 20 µl of
reaction mixtures were (3.3 µg of type I collagen) loaded to 4-15% gradient Bio-Rad MiniProtean® TGXTM Gels. Gels were stained in Coomassie Brilliant Blue, G250 and imaging was
performed using scanner.
Cell culture: All the cell culture reagents were purchased from Invitrogen (Carlsbad, CA, USA).
MDA-MB-231cells (American Type Culture Collection, Manassas, VA) were cultured on 10-cm
plates (BD biosciences) at 37C and 5% CO2 in Iscove’s Modified Dulbecco’s medium with Lglutamine (IMDM), 10% fetal bovine serum, and antibiotics (1% penicillin/streptomycin and
0.5µg/ml fungizone) as described earlier 106. Cells were passaged at 1:3 ratio every 3–4 days and
subcultured by 0.25% trypsin-EDTA treatment. Cells were re-plated one day prior to experiment
so that the cell density was 80-90% on the day of the experiment.
Confocal microscopy
For live-cell imaging, cells were trypsinized at ~ 80% confluency, seeded to Poly-Dlysine coated 35mm-glass bottom dishes (MatTek; Ashland, MA) and grown overnight in
complete medium, as described previously (Dana et al. 2013). Cells were treated with (0.05%
Dimethyl-sulfoxide, DMSO) or Cathepsin-L inhibitor (750nM) inhibitors overnight, as
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mentioned in the text. Prior to imaging, cells were treated with the substrate (Z-FR-AMC) for 23 mins.
Images of live cells were acquired using an inverted Leica TCS-SP5 confocal
microscope (Leica; IL) by Plan apochromat 63x1.4 oil objective lens. An argon ion laser (25%)
was used to generate excitation at 488nm, and pinholes were typically set to 1–1.5 Airy units.
Wound-healing cell migration assay: For wound healing experiments, MDA-MB-231 cells were
grown to confluence in a 6-well plate. Prior creating wound with a sterile pipette tip, the cells
were treated with the vehicle control (0.05% Dimethyl-sulfoxide, DMSO) or Cathepsin-L
inhibitor (750nM). Floating cells were removed by washing once with PBS. Images were
captured by 4x objective at different time intervals.
Images were captured right after the scratch (‘wound’), t=0h, to record the initial area of
the wounds, followed by image acquisition at t=22hrs to measure the recovery of the wounded
area by cell migration under different conditions. The area of the ‘wound’ was quantified by
ImageJ software1.4 by polygon selection mode
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. The migration of cells towards the

denuded area (‘wound’) was expressed as a percentage of wound closure as:
% of wound closure = [(At = 0 h – At = Δ h)/At = 0 h] × 100%,
where At = 0 h is the area of the wound measured immediately after the scratch, and At = Δ h is the
area of the wound after 22 hrs.
Statistical analysis
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Each experiment was performed a minimum of three times, and differences between
groups were determined using the unpaired Student’s t test. The data were evaluated as the mean
+ 1 s.d.
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Chapter 3
Development and Evaluation of Peptidyl
Vinylsulfonate as:
II. An Activity-Based Probe of Cathepsin L
(KDP-1)
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3.7 Transformation of Potent Specific Cathepsin L Inhibitor to Activity-Based
Probe
Functional roles of cysteine cathepsins in cancer cells often remain poorly understood.
Although, many biochemical techniques including traditional genomic and proteomic have been
utilized, often they provide the information only about the change in expression levels of the
proteins. These parameters do not correlate with the cysteine cathepsins activity as they are
expressed as inactive zymogens or exist in complex with their endogenous inhibitors.157 For
example, a protease could be present in low abundance but may still be actively turning over its
substrate. Because the activity of a protein is directly correlated to its function in vivo and given
the fact that many proteins are post-translationally modified, an activity-based assessment of an
enzyme is more directly relevant to its functional roles.158 Thus, the growing interest lies in
correlating enzyme activity with its biological manifestation, such as oncogenic transformation
or metastasis.
In this study, we seek to develop the first small molecule probe of cathepsin L that is
highly sensitive, cell permeable, non-basic, and exquisitely selective. A photoaffinity-based
cathepsin L probe has recently been reported.157 However, it suffers from severe limitations,
which makes it totally incompatible for in vivo monitoring of cathepsin L activity in a natural
cellular environment. These caveats mainly includes its (i) non-cell permeability that requires
labelling experiments to be performed only after cell lysis, (ii) low affinity (Ki = 3.6 µM) and
poor selectivity against analogous cathepsins (~only 3-6 fold against cathepsin S, K, and B).
Thus, it is critically important to develop a small molecule cathepsin L inhibitor first which will
covalently and irreversibly inactivate cathepsin L by targeting active site catalytic cysteine
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residue. The inhibitory agent must also be selective, highly potent, stable, cell permeable, and
non-basic in nature. We have developed a novel non-basic small molecule inhibitor of cathepsin
L (KD-1) that is highly potent, selective and cell permeable. Careful investigation revealed that
inclusion of an alkynyl moiety at 4-position of Cbz group will presumably retain the inhibitor
activity towards cathepsin L while rendering it with a handle for a plausible copper-based click
chemistry. The developed probe KDP-1 would find extensive usage in a variety of research
applications, relevant to cathepsin-based anti-cancer drug development endeavors. These, for
instances, may include (a) in situ tumor models for probing cathepsin L function, (b) validation
of cathepsin L as a viable therapeutic target in individual cancer types, (c) assessment of in vivo
pharmacodynamics property and efficacy of drug candidates, and (d) estimation of drug’s
selectivity and off-target reactivity137, (e) investigating the importance of targeting cathepsin L
alone in cancer cells that overexpress both cathepsin L and B; this is especially important given
the fact these two share a common physiological protein substrate of extracellular matrix, a
protein known to promote metastasis43 and (f) profiling the selectivity of cathepsin L-directed
anti-cancer drug candidates in vivo.137, 159

3.8 Chemistry
Synthesis of KDP-1 was carried out according to scheme 3.2. Synthesis of P2 was
achieved by treating 4-ethynyl benzylalcohol with triphosgene with sodium carbonate under
anhydrous condition following a literature reported protocol.160 This was used for the next step
without further purification. Chloroformate (P2) was dropwise added to a stirred slurry of
methyl ester of phenyl alanine and sodium carbonate in water/toluene mixture to obtain
intermediate P3.161 Ester hydrolysis was carried out by treating P3 with lithium hydroxide in
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equimolar mixture of water and THF162. The free acid P4 thus obtained, was utilized in further
steps to obtain KDP-1.

Scheme 3.2. Synthetic route adopted for the development of KDP-1.

3.9 Results and Experimental Propositions
The inhibitory efficacy of KDP-1 was evaluated against cathepsin L by following enzyme
kinetics method. A, dose-dependent experiment was performed at various inhibitor
concentrations and the progress curves were recorded under pseudo-first order conditions (i.e.
[KDP-1]>>[Cat. L]). Analysis of the progress curves58 established KDP-1 as one of the most
potent activity based probe known for cathepsin L (figure 3.5) (second order inactivation rate
constant (kinact) = 4.3 x 105 M-1s-1).
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Figure 3.8. [A] Time-dependent inhibition of human cathepsin L by KDP-1. Progress curves
for cathepsin L-catalyzed hydrolysis of fluorescent substrate, Z-Phe-Arg-(7-amino-4methylcoumarin), in the absence and presence of appropriate concentration of KDP-1. [B]
Determination of second order inactivation rate constant (kinact) for KDP-1-mediated
inhibition of human liver cathepsin L. The kobs obtained from the progress curve fit were
plotted against appropriate concentrations of KDP-1. The slope of the line yielded the
enzyme inactivation rate constant kinact.

The effectiveness of KDP-1 to report the intracellular cathepsin L activity will be
demonstrated in variety of carcinoma and normal cell lines. Detection of covalently modified
cathepsin L will be accomplished using click chemistry approach. This technique offers an
unique tag-less strategy to assess enzyme activity at proteome level in live cells.163 Click
chemistry protocol allows formation of a triazole ring between two functional units (i.e. between
acetylene and azide). Initially recombinant human liver cathepsin L will be incubated with KDP109

Incubate cell permeable cathepsin L probe, KDP-1,
with metastatic and non-metastatic cancer cells

1. Cell Lysis
2. Detection using

Cu-Mediated
Click Chemistry

Highly Active
Cathepsin L in
Metastatic Cells

Less active
Cathepsin L in
Non-Metastatic Cells

Figure 3.9. The procedure involved in profiling intracellular cathepsin L
activity in metastatic and non-metastatic cancer cells.
1. KDP-1 will covalently and irreversibly modify cathepsin L via formation of a C-S bond with
active site catalytic cysteine residue. The covalently modified enzyme will be subjected to
aqueous friendly click chemistry protocol164 using rhodamine-azide. The rhodamide labelled
protein will be serially diluted and the samples will be resolved using 10% SDS-PAGE. Labeled
protein resolved on a denaturing gel will be visualized directly using Typhoon scanner (GE
Healthcare). This will allow detecting minute quantity of active cathepsin L (as low as pmoles110

fmoles). Once it is demonstrated in vitro; cell-based experiment will be carried out using MDAMB-231 cell lines. The process involves incubation of KDP-1 with MDA-MB-231 cells. Once
the in vivo labelling is completed, the cells will be lysed and subjected to click chemistry
followed by quantification of active enzyme by resolving it on SDS-PAGE (figure 3.6).

3.10 Future Directions
The developed activity based probe KDP-1 could be further improved by changing the
position of alkyne and amino acid substituents. Another latest strategy involving palladiummediated Suzuki-Miyuara coupling could be utilized for tag-less labelling experiments. In this
strategy, no further modification on inhibitory scaffold will be needed. KD-1-mediated
covalently modified enzyme could be subjected to a palladium catalyzed Suzuki-Miyuara cross
coupling reaction with a fluorophore containing boronic acid under physiological conditions.165
This will enable the inhibitory scaffold to label active enzyme without affecting its inhibitory
potency.
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3.11 Experimental
3.11.1 Synthesis
General.

1

H NMR spectra were recorded at either 400 or 500 MHz using CDCl3 or DMSO

as the solvent. 13C NMR spectra were recorded at either 125 or 100 MHz using CDCl3 or DMSO
as the solvent. Chemical shifts (δ) are reported in parts per million (ppm) and referenced to
CDCl3 (7.26 ppm for 1H and 77.0 ppm for 13C), DMSO (2.50 ppm for 1H and 39.5 ppm for 13C).
Coupling constants (J) are reported in Hertz (Hz) and multiplicities are abbreviated as singlet (s),
doublet (d), doublet of doublets (dd), triplet (t), triplet of doublets (td), and multiplet (m). The
mass spectra were acquired using a 6520 Accurate-Mass Quadrupole Time-of-Flight (Q-TOF)
LC/MS (Agilent Technologies, Santa Clara, CA, USA). 4-ethynylbenzyl alcohol was purchased
from Santa Cruz Biotechnology, Inc. (Dallas, Texas, USA). O-(1H-6-Chlorobenzotriazole-1-yl)1,1,3,3-tetramethyluronium hexafluorophosphate (HCTU) was purchased from peptide
international (Louisville, Kentucky, USA). All anhydrous solvents were purchased from SigmaAldrich (St. Louis, MO, USA). All other materials were purchased from Fisher Scientific Inc.
(Pittsburgh, PA, USA).
Synthesis of Activity based probe KDP-1
Synthesis of 4-ethynylbenzyl carbonochloridate (P2)
Synthesis of P2 was carried out using a literature reported protocol160. This was used for
the next step without further purification.
Synthesis of Methyl (((4-ethynylbenzyl)oxy)carbonyl)phenylalaninate (P3):
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Synthesis of this compound was carried out using a literature reported protocol161 and its
characterization was found to be consistent with the previously reported NMR spectra.162
Synthesis of (((4-ethylbenzyl)oxy)carbonyl)phenylalanine (P4)
Synthesis of this compound was carried out using a literature reported protocol and was
used for the next step without further purification.162
Synthesis of Ethyl (E)-3-(2-((((4-ethynylbenzyl)oxy)carbonyl)amino)-3-phenylpropanamido)-5methylhex-1-ene-1-sulfonate (P5)
To a stirred solution of the BOC-protected amine III (248 mg, 0.773 mmol) was added
25% solution of trifluoroacetic acid in dichloromethane (5 ml) and stirred for 1 hr. The solution
was removed in vacuo. The residue was dissolved in DMF(2 ml). To this was added a cocktail of
P4 (250 mg, 0.773 mmol), HCTU (351mg, 0.85 mmol) and N,N-diisopropylethylamine (337μl,
1.93 mmol) as a solution in anhydrous DMF (5 ml) at 0°C. Once the addition was done, ice bath
was removed and the reaction was stirred overnight. The reaction was then diluted with 50 ml of
ethyl acetate and washed with saturated ammonium chloride solution (25 ml), saturated sodium
bicarbonate solution, and with brine (25 ml). The organic layer was dried over sodium sulfate
and concentrated in vacuo. Puriﬁcation by ﬂash column chromatography (silica gel; 80:20
hexane/ethylacetate)

provided

256

mg

(yield:

63%)

of

product.

Rf

=0.25(70:30

hexane/ethylacetate) 1H NMR (400 MHz CDCl3) δ ppm: 0.87 (m, 6H), 1.31 (m, 2H), 1.38 (t, J=
7.0 Hz, 3H), 1.50 (M, 1H), 3.02 (dd, J= 13.5 Hz and 8.1 Hz, 1H), 3.09 (s, 1H), 4.14 (m, 2H),
4.36 (m, 1H), 4.62 (m, 1H), 5.08 (m, 2H), 5.33 (bs, 1H), 5.75 (bs, 1H), 5.94 (d, J= 15.2 Hz, 1H),
6.60 (dd, J=15.2 Hz and 5.1 Hz, 1H), 7.18 (d, J= 7.0Hz, 2H), 7.3 (m, 5H), 7.48 (d, J=8.2 Hz,
2H). 13C NMR (100 MHz CDCl3) δ ppm: 14.90, 21.82, 22.65, 24.60, 38.27, 42.74, 48.03, 56.64,
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66.75, 66.98, 77.76, 83.16, 122.19, 124.63, 127.58, 127.92, 129.07, 129.17, 132.36, 135.90,
136.60, 147.59, 155.72,170.41. ). LRMS [ESI-MS +ve] calculated for (C28H34N2O6S +Na)+ :
549.63, observed 549.78.
Synthesis

of

4-bromophenyl

(E)-3-(2-((((4-ethynylbenzyl)oxy)carbonyl)amino)-3-

phenylpropanamido)-5-methylhex-1-ene-sulfonate (KDP-1)
This compound was prepared using a literature reported protocol with appropriate
modification. 150 To a stirred solution of P5 (300 mg, 0.57 mmol) in acetone was added tetrabutyl
ammonium iodide (210.5 mg, 0.57 mmol) and refluxed for overnight. The mixture was
concentrated in vacuo and was dissolved in anhydrous dichloromethane (4 ml). This was added
to a stirred solution of triphenyl phosphine (299 mg, 1.14 mmol) and sulfuryl chloride (101.3 μl,
1.254 mmol) in anhydrous dichloromethane (6 ml) at 0°C. Once the addition was done, ice bath
was removed and the reaction was stirred overnight. The mixture was then concentrated in vacuo
and passed through silica (oven dried) using hexane and ethyl acetate (90:10) to recover sulfonyl
chloride as white solid. Subsequently, the sulfonyl chloride (260mg, 0.503 mmol) was dissolved
in anhydrous dichloromethane (3 ml). 4-bromophenol (130 mg, 0.76 mmol) was added to the
solution followed by addition of triethylamine (140 μl, 1.01 mmol) at 0°C. The mixture was
stirred for one hr and diluted with ethyl acetate (30 ml) followed by washing with saturated
ammonium chloride solution (15 ml), saturated sodium bicarbonate solution (15ml ×3), and with
brine (15 ml). The organic layer was dried over sodium sulfate and concentrated in vacuo.
Puriﬁcation by ﬂash column chromatography (silica gel; 90:10 hexane/ethylacetate) provided
125 mg (after three steps yield: 40%) of the product as white solid. Rf = 0.52 (70:30
hexane/ethylacetate). 1H NMR (400 MHz CDCl3) δ ppm: 0.82 (m, 6H), 1.22 (m, 2H), 1.41 (m,
1H), 2.99 (dd, J= 13.5 and 8.4 Hz, 1H), 3.10 (dd, J= 13.5 and 8.4 Hz, 1H), 3.10 (s, 1H), 4.37 (m,
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1H), 4.53 (m, 1H), 5.06 (m, 2H), 5.44 (bd, J=7.1 Hz, 1H), 5.89 (bd, J=5.2 Hz, 1H), 6.04 (d,
J=15.1 Hz, 1H), 6.47 (dd, J= 15.1 and 5.3 Hz, 1H), 7.08 (m, 2H), 7.13 (m, 2H), 7.28 (m, 5H),
7.49 (m, 4H)

13

C NMR (100 MHz CDCl3) δ ppm: 21.85, 22.53, 24.57, 38.38, 42.34, 48.26,

56.65, 66.75, 77.83, 83.16, 120.84, 122.20, 123.86, 124.45, 127.64, 127.88, 129.09, 129.15,
132.36, 132.94, 135.86, 136.57, 148.36, 149.96, 155.93, 170.54 ). LRMS [ESI-MS +ve]
calculated for (C32H33BrN2O6S +Na)+ : 676.57, observed 676.66.

3.11.2 Enzyme Kinetics
Inhibitory efficacy of KDP-1 was assessed against cathepsin L by following the same
protocol that has been adopted for inhibitor KD-1.
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Appendix A: NMR Spectra of Synthesized Arylsulfonyloxiranes.
2-(4-Fluorophenyl)-3-(phenylsulfonyl)oxirane (1):
F

O2
S
1

H NMR:

O

13

C NMR:

13

C DEPT45:
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2-(Phenylsulfonyl)-3-propyloxirane (2):
O2
S
1

H NMR:

O

13

C NMR:
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2-(4-Chlorophenylsulfonyl)oxirane (3).
O2
S
1

H NMR:

Cl
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C NMR:
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2-((4-Trifluoromethoxy)phenylsulfonyl)oxirane (4).
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2-(2-Ethylphenylsulfonyl)oxirane (5).
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2-(m-Tolylsulfonyl)oxirane (6).
O2
S
O
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H NMR:

13

C NMR:
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2-(2,5-Dimethylphenylsulfonyl)oxirane (7):
O
O S O
1

H NMR:

13

C NMR:
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2-(3-Methoxyphenylsulfonyl)oxirane (8):
O2
S
O
1

H NMR:

OCH3

13

C NMR:
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2-(2,5-Dimethoxyphenylsulfonyl)oxirane (9):
H3CO
1

H NMR:

O2
S
O
OCH3

13

C NMR:
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2-(3,5-dichlorophenylsulfonyl)oxirane(10):
O2
S

Cl

O
1

H NMR:

Cl

13

C NMR:
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(j) 2-(Naphthalen-3-ylsulfonyl)oxirane (11):
O2
S
1

O

H NMR:

13

C NMR:
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Appendix B: NMR Spectra of Synthesized Allyl/Vinyl Sulfones and Crystal Structure of
(E)-((3-phenylprop-1-en-1-yl)sulfonyl)benzene (2)

Figure: 1H and 13C NMR spectrum of 2.
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Figure: 1H-1H COSY spectrum of 2. Observed crosspeaks establish the connectivity between
protons 1, 2, and 3 as well as between the ortho, meta, and para protons of the phenyl rings.
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Figure:

13

C-1H heteronuclear COSY spectrum of 2. Observed crosspeaks establish the

assignment of protons and the carbons directly attached to it. C3 and H3 are not shown in the
figure and their crosspeak is observed at (37.64, 3.56).
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Figure: 1H-13C HMBC spectrum of 2. Peaks marked A to G are assigned as follows. A: Hc-Ca B:
Hc’’-Ca’ C: H2-Ca’ D: H3-C2 E: H3-Ca’ F: H3-C1 G: H3-Cb’ . The long range 1H and

13

C

connectivity illustrated through peaks A to G help establish the assignment of quaternary carbons
a and a’ as well as distinguish the two rings. Olefinic proton 2 and aliphatic proton 3 and show
three bond coupling to Ca’ and Cb’ respectively which clearly establishes the position of double
bond with respect to the phenyl ring.
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Figure: 1H and 13C NMR spectrum of 3.
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Figure: 1H and 13C NMR spectrum of 4.
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Figure: 1H and 13C NMR spectrum of 5.
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Figure: 1H and 13C NMR spectrum of 6.
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Figure: 1H and 13C NMR spectrum of 7.
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Figure: 1H and 13C NMR spectrum of 8.
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Figure. 1H and 13C NMR spectrum of 9.
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Figure: 1H-1H COSY spectrum of 9. Observed crosspeaks establish the connectivity between
protons 1, 2, and 3 as well as between the phenyl ring protons b, c, and d.
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Figure:

1

H-13C heteronuclear HSQC spectrum of 9. Observed crosspeaks establish the

assignment of protons and the carbons directly attached to it. H1 and C1 are not shown in the
figure and their crosspeak is observed at (3.96, 60.51).
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Figure: 1H-13C HMBC spectrum of 9. Peaks marked A to E are assigned as follows. A: Hc-Ca B:
H3-Cb’ C: Hc’’-Ca’ D: H3-Cb’ E: H2-Ca’. The long range 1H and

13

C connectivity illustrated

through peaks A to E help establish the assignment of quaternary carbons a and a’ as well as
distinguish the two rings. Olefinic protons 2 and 3 show three bond coupling to Ca’ and Cb’
respectively which clearly establishes the position of double bond with respect to the phenyl
ring.
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Figure: 1H and 13C NMR spectrum of 10.
141

Figure: 1H and 13C NMR spectrum of 11.
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Figure: 1H and 13C NMR spectrum of 12.
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Figure: 1H and 13C NMR spectrum of 13.
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Figure: 1H and 13C NMR spectrum of 14.
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Figure: 1H and 13C NMR spectrum of 15.
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16E

16Z

Figure: 1H and 13C NMR spectrum of 16E and 16Z.
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Figure: 1H-1H COSY spectrum of the mixture of 16E and 16Z
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Figure:

13

C-1H heteronuclear correlation spectrum of the mixture of 16E and 16Z. Aliphatic 1H-

13

C crosspeaks for both compounds are illustrated in the figure.
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19E

19Z

Figure: 1H and 13C NMR spectrum of 19E and 19Z.
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Figure: 1H-1H COSY spectrum of the mixture of 19E and 19Z
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1e

3e

Figure:
1

13

1z

2e, 2z
3z

C-1H heteronuclear correlation spectrum of the mixture of 19E and 19Z. Aliphatic

H-13C crosspeaks for both compounds are illustrated in the figure.
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Figure: 1H and 13C NMR spectrum of 24.
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X-ray Structure Determination of Compound 2
A clear fragment of 2 with approximate dimensions 0.18 mm x 0.40 mm x 0.51 mm, cut from a
cluster of crystals obtained by crystallization at room temperature from ethyl acetate/hexanes,
was used for the X-ray crystallographic analysis. The X-ray intensity data were measured on a
Bruker Smart Breeze CCD system equipped with a graphite monochromator at 100(2) K, cooled
by an Oxford Cryosystems 700 Series Cryostream. A total of 1464 frames were collected. The
total exposure time was 4.07 hours.

The frames were integrated with the Bruker SAINT

software package using a narrow-frame algorithm. The integration of the data using a monoclinic
unit cell yielded a total of 7242 reflections to a maximum θ angle of 27.26° (0.78 Å resolution),
of which 2900 were independent (average redundancy 2.497, completeness = 99.8%, Rint =
2.07%, Rsig = 2.62%) and 2850 (98.28%) were greater than 2σ(F2). The final cell constants of a
= 5.6179(5) Å, b = 7.6160(6) Å, c = 15.3045(13) Å, β = 95.8260(10)°, volume = 651.43(10) Å3,
are based upon the refinement of the XYZ-centroids of 4601 reflections above 20 σ(I) with
5.349° < 2θ < 54.435°. Data were corrected for absorption effects using the numerical method
(SADABS). The ratio of minimum to maximum apparent transmission was 0.915. The calculated
minimum and maximum transmission coefficients (based on crystal size) are 0.8883 and 0.9583.
The structure was solved and refined using the Bruker SHELXTL Software Package,
using the space group Pn, with Z = 2 for the formula unit, C15H14O2S. The final anisotropic fullmatrix least-squares refinement on F2 with 163 variables converged at R1 = 2.80%, for the
observed data and wR2 = 7.00% for all data. The goodness-of-fit was 1.065. The largest peak in
the final difference electron density synthesis was 0.231 e¯/Å3 and the largest hole was -0.179
e¯/Å3 with an RMS deviation of 0.040 e¯/Å3. On the basis of the final model, the calculated
density was 1.317 g/cm3 and F(000), 272 e¯.
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Cambridge Crystallographic Data Centre deposition number for 2: CCDC 916842. The
data

can

be

obtained

free

from

Cambridge

Crystallographic

Data

Centre

via

http://www.ccdc.cam.ac.uk/data_request/cif.

Figure S28. ORTEP1 drawing of 2 with complete numbering of atoms, viewed approximately
normal to the alkene plane. Selected bond lengths (Å) and angles (°): S1-O1, 1.443(1); S1-O2,
1.443(1); S1-C1, 1.753(2); S1-C4, 1.760(2); C1-C2, 1.320(2); C2-C3, 1.504(2); C3-C10,
1.525(2)O1-S1-O2, 118.37(8); O1-S1-C1, 109.14(7); O2-S1-C1, 107.07(8); O1-S1-C4,
108.38(7); O2-S1-C4, 108.07(7), C1-S1-C4, 105.01(7); C2-C1-S1, 120.9(1); C1-C2-C3,
124.6(2); C2-C3-C10, 110.3(1).
1

Farrugia, L. J., J. Appl. Crystallogr. 1997, 30, 565.
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Appendix C: NMR Spectra of Synthesized Vinyl Sulfonates
4-Bromophenyl ethenesulfonate (1):

Figure: 1H and 13C NMR spectrum of 1
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Quinolin-8-yl ethenesulfonate (2):

Figure. 1H and 13C NMR spectrum of 2.
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5-Nitroquinolin-8-yl ethenesulfonate (3):

Figure. 1H and 13C NMR spectrum of 3.
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[1,1’-Biphenyl]-4-yl ethenesulfonate (4):

Figure. 1H and 13C NMR spectrum of 4.
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4’-Nitro-[1, 1’-biphenyl]-4-yl ethenesulfonate (5):

Figure. 1H and 13C NMR spectrum of 5.

160

Methyl 2-((vinylsulfonyl) oxy) benzoate (6):

Figure. 1H and 13C NMR spectrum of 6.

161

Methyl 4-((vinylsulfonyl) oxy) benzoate (7):

Figure. 1H and 13C NMR spectrum of 7.

162

4-Cyanophenyl ethenesulfonate (8):

Figure. 1H and 13C NMR spectrum of 8.

163

4-Nitrophenyl ethenesulfonate (9):

Figure. 1H and 13C NMR spectrum of 9.

164

5-Fluoro-2-nitrophenyl ethenesulfonate (10):

Figure. 1H and 13C NMR spectrum of 10

165

4-Chlorophenyl ethenesulfonate (11):

166

Figure. 1H and 13C NMR spectrum of 11

2-Chlorophenyl ethenesulfonate (12):

Figure. 1H and 13C NMR spectrum of 12.
167

3-Chlorophenyl ethenesulfonate (13):

Figure. 1H and 13C NMR spectrum of 13

168

4-Chloro-2-fluorophenyl ethenesulfonate (14):

Figure. 1H and 13C NMR spectrum of 14

169

4-Chloro-3-fluorophenyl ethenesulfoante (15):

Figure. 1H and 13C NMR spectrum of 15.

170

4-Chloro-3-(trifluoromethyl) phenyl ethenesulfonate (16):

Figure. 1H and 13C NMR spectrum for FN-16

171

4-Chloro-2, 3, 5, 6-tetrafluorophenyl ethenesulfonate (17):

Figure. 1H and 13C NMR spectrum of 17

172

4-Chloro-3-methylphenyl ethenesulfonate (18):

Figure. 1H and 13C NMR spectrum of 18

173

4-Chloro-3, 5-dimethylphenyl ethenesulfonate (19):

Figure. 1H and 13C NMR spectrum of 19

174

4-Chloro-2-nitrophenyl sulfonate (20):

Figure. 1H and 13C NMR spectrum of 20.

175

3, 4-Dichlorophenyl ethenesulfonate (21):

Figure. 1H and 13C NMR spectrum of 21.

176

2, 4, 5- Trichlorophenyl ethenesulfonate (22):

Figure. 1H and 13C NMR spectrum of 22.
177

2, 4, 6-Trichlorophenyl ethenesulfonate (23):

Figure. 1H and 13C NMR spectrum of 23.
178

Methyl 5-chloro-2-((vinylsulfonyl) oxy) benzoate (24):

Figure. 1H and 13C NMR spectrum of 24

179

4-Fluorophenyl ethenesulfonate (25):

Figure. 1H and 13C NMR spectrum of 25.

180

4-Iodophenyl ethenesulfonate (26):

Figure. 1H and 13C NMR spectrum of 26.
181

2-Ethylphenyl ethenesulfonate (27):

Figure. 1H and 13C NMR spectrum of 27

182

Ethyl (E)-3-((tert-butoxycarbonyl)amino)-5-methylhex-1-ene-1-sulfonate (III)

Figure. 1H and 13C NMR spectrum of III.
183

Ethyl(E)-3-(2-(((benzyloxy)carbonyl)amino)-3-phenylpropanamido)-5-methylhex-1-ene-1sulfonate (IV)

Figure. 1H and 13C NMR spectrum of IV.

184

4-bromophenyl(E)-3-(2-(((benzyloxy)carbonyl)amino)-3-phenylpropanamido)-5methylhex-1-ene-1-sulfonate (KD-1)

Figure. 1H and 13C NMR spectrum of KD-1.
185

Ethyl (E)-3-(2-((((4-ethynylbenzyl)oxy)carbonyl)amino)-3-phenylpropanamido)-5-methylhex-1-ene-1sulfonate (P5)

Figure: 1H and 13C NMR spectrum of P5.

186

4-bromophenyl (E)-3-(2-((((4-ethynylbenzyl)oxy)carbonyl)amino)-3-phenylpropanamido)-5-methylhex-1-enesulfonate (KDP-1)

Figure: 1H and 13C NMR spectrum of KDP-1.
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